



CURRICULUM VITAE

(Revised January 2015)

Dr. Andreas Scorilas, Ph.D *Professor of Clinical Biochemistry*

Date and Place of Birth: 1968, Arta-Ano Kalentini, Western Greece
Work address: University of Athens, Department of Biochemistry and Molecular Biology, Biochemistry Lab, 15701, Panepistimiopolis, Ilisia, Athens, Greece.
Tel: +30-210-727-4306, Fax: +30-210-727-4158
E-mail: ascorilas@biol.uoa.gr Web: <http://users.uoa.gr/~ascorilas>

Languages

Greek and English

Elementary Education

Elementary School in Arta-Ano Kalentini and High School in Athens, Greece, Graduation, June 1986

Education

1. Postdoctoral training, *Clinical Biochemistry - Pathobiology*, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada. (1998-2002).
2. Ph.D., *Biochemistry - Molecular Biology*, "G. Papanicolau" Research Center of Oncology and Medical School, University of Athens. (1992-96)
3. B.Sc.(Hon), *Chemistry*, University of Ioannina, Ioannina, Greece (1986-1990)

Present Positions

Professor, Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece.

Head, Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece.

Head, Post Graduate Program: Clinical Biochemistry-Molecular Diagnostics, University of Athens, Greece.

Research Records

- ❖ **236** publications in international peer review scientific journals, including publications in top class journals such as *Clinical Chemistry*, *Journal of Clinical Oncology*, *Nature Medicine*, *Cancer Research*, *Clinical Cancer Research* etc.
- ❖ Total Impact Factor, **I.F = 1013 (4.3 / publication)**
- ❖ **5900 citations** (*Scopus, January, 2015*)
- ❖ **h-Index = 42** (*Scopus, January, 2015*)

- ❖ **5 Patents**
- ❖ **248** publications in proceedings of international conferences.
- ❖ **50** original complete gene entries in NCBI GeneBank
- ❖ **6** Books and 10 Book chapters
- ❖ **63** publications in Greek
- ❖ Coordinator in **20** accomplished national and international research grants

Overview of Research Activities

- Discovery and validation of novel molecular tumor biomarkers
- Molecular diagnostic methodologies
- Next generation sequencing
- miRNAs
- Cancer pharmacogenomics and therapeutics
- Mechanisms of carcinogenesis and cancer progression
- Translational Research

Research Achievements

- ❖ Discovery, cloning and identification of the following novel cancer-related genes:
 - The novel apoptotic *BCL2L12* gene
 - The new carcinoembryonic antigen gene *CEAL1 (CEACAM19)*
 - The *SR-A1* gene (*SCAF1*)
 - *TSKS, AP2A1* etc
- ❖ Characterization and study of the kallikrein gene family members *KLK7, KLK11, KLK15*
- ❖ Elucidation of the clinical significance of kallikrein genes, L-Dopa decarboxylase (*DDC*) gene and other cancer-related genes, in several human malignancies.
- ❖ Development of novel bioanalytical methodologies, useful in Biochemistry and Molecular Diagnostics.

Distinctions and Awards

A. Major Awards and Distinctions

- *Ranked among the top 3 Researchers-Authors in Europe and the top 6 globally- in the field of Biological Tumor Markers (Biomed Experts, 2014).*
- *National Academy of Clinical Biochemistry Award, Los Angeles, USA, 2012.*

- *E.K. Frey - E. Werle Promotion Prize*, International Scientific Award, Munich, Germany, 2009.
- *Guest Editor of 8 Highlight Issues of the Journals: Biological Chemistry, Thrombosis and Haemostasis, Current Chemical Biology, Anti-Cancer Agents in Medicinal Chemistry, International Scholarly Research Notices, Austin Proteomics, and Austin Journal of Molecular and Cellular Biology.*
- *"Dionysios Razis" Scientific Award*, Athens, Greece, 2009.
- *The World Metal of Freedom, American Biographical Institute*, North Carolina, US, 2008.
- *"Greek Society of Men of Letters" Scientific Award*, Athens, Greece, 2008.
- *Empeirikeion Grant Award*, Athens, Greece, 2007.
- *Elected Fellow of the International Academy of Clinical and Applied Thrombosis/Haemostasis*, New York, US, 2004.

B. Referee for Grant Agencies and Scientific Journals

- | | |
|---|--|
| 1. Seven Framework Program (FP7), European Union (Health, Cancer Section) | 24. Clinical Cancer Research |
| 2. Cancer Research UK | 25. Clinical Chemistry |
| 3. Health Research Board (HRB) of Ireland | 26. Current Pharmaceutical Design |
| 4. General Secretary for Research and Technology of Greece | 27. Disease Markers |
| 5. Internal Grant Agency of Czech Republic | 28. Endocrinology |
| 6. Dutch Internal Grant Agency | 29. Expert Opinion on Emerging Drugs |
| 7. Internal Grant Agency of Romania | 30. Expert Review of Anticancer Therapy |
| 8. BBA - Molecular Cell | 31. Expert Review on Molecular Diagnostics |
| 9. BBA Molecular Basis Disease | 32. European Journal of Pharmacology |
| 10. Biochemical Pharmacology | 33. FEBS Journal |
| 11. Biological Chemistry | 34. Future Oncology |
| 12. BMC Cancer | 35. Gene |
| 13. BMC Molecular Biology | 36. Genome Medicine |
| 14. Breast Cancer Research | 37. Hormones Journal |
| 15. British Journal of cancer | 38. In Vitro Cellular & Developmental Biology |
| 16. British Journal of Pharmacology | 39. International Journal of Cancer |
| 17. Cancer Chemotherapy and Pharmacology | 40. ISRN Oncology |
| 18. Cancer Epidemiology, Biomarkers & Prevention | 41. Journal of Experimental & Clinical Cancer Research |
| 19. Canadian Medical Association Journal - CMAJ Open | 42. J Biological Research |
| 20. Cancer Letters | 43. J Cancer Science Therapy |
| 21. Cancer Research | 44. J Clinical Endocrinology & Metabolism |
| 22. Clinica Chimica Acta | 45. J Medicinal Chemistry |
| 23. Clinical Biochemistry | 46. J Surgical Oncology |
| | 47. Journal of Biomedicine and Biotechnology |
| | 48. Journal of Oncology |

- | | |
|--|--|
| 49. Journal of Photochemistry and Photobiology A Chemistry | 58. Prostate Cancer |
| 50. Mammalian Genome | 59. Talanta |
| 51. Methods and Findings in Experimental and Clinical Pharmacology | 60. The International Journal of Biochemistry & Cell Biology |
| 52. Molecular Cancer | 61. The Protein Journal |
| 53. Molecular Oncology | 62. The World Journal of Hypertension |
| 54. Molecular and Cellular Biochemistry | 63. Thrombosis and Haemostasis |
| 55. Nature Reviews Urology | 64. Tumor Biology |
| 56. Oncogene | |
| 57. Protein Expression & Purification | |

C. Invited Speaker

1. Invited plenary lecturer in the INSPiRE International Conference-Oncogenic pathways and anti-tumor responses, Athens, Greece, 2014.
2. Invited plenary lecturer in 5th International Symposium on Kallikreins and Kallikrein-Related peptidases, Toronto, Canada, September, 2013.
3. Invited speaker in 64th Congress of the Hellenic Society of Biochemistry and Molecular Biology, Athens, December 2013
4. Invited speaker in Breast Cancer and tumors of the female reproductive tract meeting, Athens, December 2013.
5. Invited speaker in "2nd International Conference and Exhibition on Cell & Gene Therapy", Florida, USA, 2013.
6. Invited plenary lecturer in 62nd Hellenic Society for Biochemistry and Molecular Biology Conference, Athens, Greece, December 2011.
7. Invited speaker in EORTC (European Organization for Research and Treatment of Cancer), Head and neck cancer group meeting, Brussels, Belgium, March 2010
8. Invited plenary lecturer in 8th Tumor Markers - Targeted Therapy Congress, Athens, Greece, November 2010.
9. Invited speaker in 9th Conference of the Greek Society of Clinical Chemistry under the title "Novel prognostic and diagnostic cancer biomarkers", October 2010
10. Invited speaker in the workshop of Hellenic Society of Pathological Anatomy, under the title "Principles of Molecular and Cellular Biology", Athens, Greece, May 2010.
11. Invited plenary lecturer in 3rd International Symposium on Kallikreins and Kallikrein-Related peptidases, Munich, Germany, August-September 2009
12. Invited speaker in Biomedical Asia 2009 International Conference, Singapore, 2009.
13. Invited plenary lecturer, 3rd Euro-Mediterranean congress on Oncology Radiology, Tozeur, Tunisia, October 2008.
14. Invited plenary lecturer, 3rd Conference on Diagnostic, Predictive and Experimental Oncology, Olomouc, Czech republic, November 2007.
15. Invited speaker, 4th Hellenic symposium on breast cancer, April 2007

16. Invited plenary lecturer, 8^{ème} Seminaire Sur Les Cancers Du Cavum, de la biologie a la therapeutique, SFax ,Tunisia, January 2007.
17. Invited lecturer, 3^o Pan-Hellenic anticancer conference, April 2007.
18. Invited plenary lecturer, 6^o Pan-Hellenic Symposium of Clinical Chemistry, Athens, Greece, November 2006.
19. Invited plenary lecturer, 8th Annual Meeting of the Hellenic Research Club for Connective Tissue & Matrix Biology, Heraklion, Greece, April 2006.
20. Invited speaker in seminars of Clinical Research Unit / Dept. Obstetrics and Gynecology, Medical School , Technical University of Munich - Germany , November 2005.
21. Invited speaker, scientific symposium of 4th Surgery Department, 'Attikon' University General Hospital, June 2005.
22. Invited plenary lecturer, International Congress of Laboratory Medicine: Enzymes Meet Proteomics, Padova, Italy, October 2004.
23. Invited plenary lecturer, 4^o Mediterranean Conference of Laboratory Medicine, Bari, Italy, December 2004.

D. Invitation for review articles

- Expert Review of Molecular Diagnostics, 2014
- Expert Opinion on Therapeutic Targets, 2013
- Anti-Cancer Agents in Medicinal Chemistry, 2013
- Clinical Chemistry and Laboratory Medicine, 2012
- Advances in Hematology, 2011
- Biological Chemistry, 2011
- Biological Chemistry, 2010
- Genome Medicine, 2010
- Future Oncology, 2009
- Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2009
- Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2008
- Mini-Reviews in Medicinal Chemistry, 2006
- Critical Review of Clinical Laboratory Science, 2005
- Clinical Laboratory, 2004
- Critical Review of Clinical Laboratory Science, 2001

Previous Positions

- 2008-2013:** *Associate Professor*, Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece. University of Athens
- 2003-2008:** *Assistant Professor*, Department of Biochemistry and Molecular Biology, University of Athens, Athens, Greece. University of Athens
- 2002-2003:** *Research Associate Scientist*, Biomolecules Lab, National Centre for Scientific Research (NCSR) "Demokritos", Athens, Greece.
- 1998-2002:** *Postdoctoral Fellow - Research Associate*, Department of Pathology & Laboratory Medicine, Mount Sinai Hospital and Department of Laboratory Medicine & Pathobiology, University of Toronto, Ontario, Canada.
- 1997-1998:** *Clinical Research Scientist*, Laboratory of Immunochemistry and *in situ* Hybridization, Pathology Department and Research Unit, 401 Army General Hospital of Athens, Athens, Greece (Army Service).
- 1996-1997:** *Clinical Research Scientist*, Laboratory of Microbiology and Biochemistry, Pathology, 412 Army General Hospital, Xanthi, Greece (Army Service).
- 1995-1996:** *Research Associate*, Department of Virology, "G. Papanicolaou" Research Center of Oncology, National Anticancer Institute, "St. Savvas" Hospital, Athens, Greece (Research Associate in Greece-Italy Co-operation Project).
- 1991-1993:** *Research Associate*, Department of Biochemistry and Molecular Biology, "G. Papanicolaou" Research Center of Oncology, Athens, Greece.
- 1989-1990:** *Research Assistant*, Department of Organic Chemistry and Biochemistry, University of Ioannina, Ioannina, Greece.

Experience in Education

- ❖ Head of the post graduate program: Clinical Biochemistry-Molecular Diagnostics, University of Athens, (2014-today)
- ❖ Coordination and teaching in the postgraduate courses "Pathobiochemistry" in the Postgraduate program of Clinical Biochemistry - Molecular Diagnostics (Academic years: 2003-today).
- ❖ Coordination and teaching in the postgraduate courses "Pathobiochemistry" in the Postgraduate program of Clinical Biochemistry - Molecular Diagnostics (Academic years: 2003-today).
- ❖ Coordination and teaching in the postgraduate courses "Clinical Chemistry" in the Postgraduate program of Clinical Biochemistry - Molecular Diagnostics (Academic years: 2003-today).
- ❖ Coordination and teaching in the postgraduate courses "Biostatistics-Bioinformatics" in the Postgraduate program of Clinical Biochemistry - Molecular Diagnostics (Academic years: 2003-today).

- ❖ Coordination and teaching in the postgraduate course "Molecular Diagnostics" in the Postgraduate program of Molecular Medicine (Academic years: 2005- today).
- ❖ Teaching in the postgraduate course "Molecular bases off human diseases" in the Postgraduate program of Clinical Biochemistry - Molecular Diagnostics (Academic years: 2006- today).
- ❖ Teaching in the postgraduate course "Laboratory Management" in the Postgraduate program of Clinical Biochemistry - Molecular Diagnostics (Academic years: 2006- today).
- ❖ Teaching of the postgraduate course entitled "Molecular Diagnostics" in the M.Sc. program in Clinical Chemistry, University of Athens (Academic years: 2000- today).
- ❖ Organized and taught one full course entitled "Clinical Chemistry" as well as relevant laboratory practicals to third year undergraduate students of Biology, at University of Athens, Greece (Academic years: 2003- today).
- ❖ Organized and taught one full course, as well as relevant laboratory practicals in the course entitled "Characterization and analysis of Nucleic Acids and Proteins: Basic Molecular Techniques" in PhD students of NCSR "Demokritos", Greece (Academic years: 2001-2008).
- ❖ Teaching of the course entitled "Chemometrics-Biostatistics" in the M.Sc. program in Clinical Chemistry, University of Athens (Academic years: 2000-2008).
- ❖ Supervision in 3 "four year projects" carried out by fourth year undergraduate students in the Department of Laboratory Medicine and Pathobiology, University of Toronto (1998-2000).
- ❖ Supervisor of 25 "four year projects" carried out by fourth year undergraduate students in the Department of Biochemistry and Molecular Biology, University of Athens (2003-).
- ❖ Supervision of 15 Master thesis carried out in University of Athens (2003-).
- ❖ Supervision of 10 PhD thesis carried out in University of Athens (2003-).
- ❖ 16 university teaching books, book chapters and webcast.

Scientific Conferences and Symposia

A. Organization

- ❖ INsPiRE 2014: International Congress on Tumor Biomarkers, Athens, Greece, 2014 (President).
- ❖ International Society of Enzymology, meeting, Kos, Greece, 2014 (President).
- ❖ 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), Toronto, Canada, 2013 (Member of the scientific committee).
- ❖ Progress in combination therapy of cancer using novel immunomodulators, Athens, Greece, 2012 (Member of the organizing committee).
- ❖ 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011), Rhodes, Greece, 2011 (President).
- ❖ ISE International Conference On Enzymes New Roles for Old Molecules: Enzymes in Personalized Medicine, Chania, Greece, 2010 (Member of the scientific committee).
- ❖ 8th Tumor Markers - Targeted Therapy Congress, Athens, Greece, 2010 (Member of the scientific committee).
- ❖ 3rd International Symposium on Kallikreins and Kallikrein-Related peptidases, Munich, Germany, 2009 (Member of the scientific committee).
- ❖ 1st International Conference on Molecular Cancer Research, Athens, Greece, 2009 (Member of the scientific committee).
- ❖ XVI Meeting of Balkan Clinical Laboratory Federation & 7th Hellenic Congress of Clinical Chemistry, Athens, Greece, 2008 (Member of the scientific committee).
- ❖ 33th FEBS Congress - 11th IUBMB Conference, Athens, Greece, 2008 (Member of the organizing committee)
- ❖ 2nd International Conference on Kallikreins, Santorini, Greece, 2007 (Co-Chair of the organizing committee)
- ❖ 5th Congress of International Proteolysis Society, Patra, Greece, 2007 (Member of the organizing committee).
- ❖ 8th Annual Meeting of the Hellenic Research Club for Connective Tissue & Matrix Biology, Heraklion, Greece, 2006. (Chair of Section 7: Development and applications of novel assays in drugs and diseases).
- ❖ 9th Conference of the Greek Society of Clinical Chemistry, Athens, 2010 (Member of the organizing committee).
- ❖ 60th Hellenic Society for Biochemistry and Molecular Biology Conference, Athens, Greece, 2009 (Member of the organizing committee).
- ❖ 4th Conference of the Greek Society of Research on Endocrinology and Metabolism Diseases, Athens, Greece, 2008 (Member of the organizing committee).

B. Oral Presentations

1. Inspire international Conference, Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.

2. International Society of Enzymology, meeting, Kos, Greece, 2014.
3. 29th Panhellenic Congress of Surgery, Athens, November, 2014.
4. 5th International Symposium on Kallikreins and Kallikrein-Related peptidases, Toronto, Canada, September, 2013.
5. 64th Congress of the Hellenic Society of Biochemistry and Molecular Biology, Athens, December 2013.
6. Breast Cancer and tumors of the female reproductive tract meeting, Athens, December 2013.
7. 18th Panhellenic Congress of Clinical Oncology, Athens, Greece, 2012.
8. 62nd Hellenic Society for Biochemistry and Molecular Biology Conference, Athens, Greece, December 2011.
9. 19th United European Gastroenterology Federation Congress, UEGW 2011, Stockholm, Sweden, October 2011.
10. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011), Rhodes, Greece, 2011.
11. 17th Panhellenic Congress of Clinical Oncology, Athens, Greece, 2011
12. 8th Tumor Markers - Targeted Therapy Congress, Athens, Greece, November 2010.
13. 8th Congress of the Balkan Union of Oncology, Sibiu, Romania, September 2010.
14. 9th Conference of the Greek Society of Clinical Chemistry under the title “Novel prognostic and diagnostic cancer biomarkers”, October 2010
15. 66th Panhellenic Orthopaedic Conference, Athens, October 2010
16. Workshop of Hellenic Society of Pathological Anatomy, under the title “Principles of Molecular and Cellular Biology”, Athens, Greece, May 2009.
17. 3rd International Symposium on Kallikreins and Kallikrein-Related peptidases, Munich, Germany, September 2009.
18. 1st International Conference on Molecular Cancer Research, Athens, Greece, November 2009
19. Biomedical Asia 2009. International Conference, Singapore, March 2009.
20. 3rd Euro-Mediterranean congress on Oncology Radiology, Tozeur, Tunisia, October 2008.
21. 3rd Conference on Diagnostic, Predictive and Experimental Oncology, Olomouc, Czech republic, November 2007.
22. 9th Annual Meeting of the Hellenic Research Club for Connective Tissue & Matrix Biology, Athens, Greece, 2007.
23. 4th Hellenic symposium on breast cancer, April 2007
24. 3rd Panhellenic Anticancer Congress, Athens, April 2007
25. 8th Symposium on Nasopharyngeal Cancers: Biology and Therapeutics, Sfax ,Tunisia, January 2007.
26. 8th Annual Meeting of the Hellenic Research Club for Connective Tissue & Matrix Biology, Heraklion, Greece, 2006.

27. 8th Symposium on Nasopharyngeal Cancers: Biology and Therapeutics, SFax ,Tunisia, January 2007.
28. 6th Pan-Hellenic Symposium of Clinical Chemistry, Athens, Greece, November 2006.
29. 4th Mediterranean Meeting of Laboratory Medicine, Bari, Italy, December 2004.
30. International Conference on Laboratory Medicine, Enzymes Meet Proteomics, Padova, Italy, October, 2004.
31. 56th Meeting of Hellenic Society of Biochemistry & Molecular Biology, Larissa, November 2004.
32. 16th International Congress on Fibrinolysis and Proteolysis, Munich, Germany, September 2002.
33. 10th Pan-Hellenic Symposium of Pharmaceutical Chemistry, Athens, Greece, January 2002.
34. American Association for Cancer Research Annual Meeting, New Orleans, USA, March 2001.
35. Annual Oak Ridge Conference of the American Association of Clinical Chemistry, Boston, USA, May 2000 .
36. American Association for Cancer Research Annual Meeting, San Francisco, USA, April 2000.
37. International Proteolysis Society First General Meeting, Michigan, USA, September 1999.
38. Department of Pathology and Laboratory Medicine Annual Symposium on Advances in Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada, June 1999.
39. American Association for Cancer Research Annual Meeting, Philadelphia, USA, April 1999.
40. International Conference of the Mediterranean Society of Tumor Marker Oncology (MESTMO): Athens, Greece, October 1994.

C. Poster Presentations

1. FEBS-EMBO 2014 Conference, Paris, France, 2014.
2. Inspire international Conference, Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
3. International Society of Enzymology Meeting (ISE), Kos, Greece, 2014.
4. XVI International Symposium of Luminescence Spectrometry, ISLS 2014, Rhodes, Greece, 2014
5. 5th International Symposium on Kallikreins and Kallikrein-Related peptidases, Toronto, Canada, September, 2013.
6. 64th Congress of the Hellenic Society of Biochemistry and Molecular Biology, Athens, December 2013.
7. Ageing and Cancer cell biology: Convergent and divergent molecular mechanisms, Athens, 2013.
8. 38th FEBS congress, Saint Petersburg, Russia, July, 2013
9. AACR 2013, Washington, USA, 2013.
10. 22nd ETRS meeting, 4-5 October 2012, Athens, Greece, 2012.
11. Advances in Circulating Tumor Cells (ACTC 2012), Athens, September 2012.
12. 37th FEBS 2012 – 22nd IUBMB, Seville, Spain, September 2012.
13. American Association for Clinical Chemistry 2012 AACC Annual Meeting, Los Angeles, CA, USA, July 2012. (*Best poster award*).

14. American Association for Cancer Research (AACR) Annual Meeting 2012, April 2012.
15. 34th Congress of the Hellenic Association of Biological Sciences, May, 2012.
16. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011), Rhodes, Greece, September 2011.
17. European Society for Medical Oncology (ESMO) 2011 Congress, Stockholm, September 2011.
18. 36th FEBS Congress, Torino (Turin), Italy, June 2011.
19. European Multidisciplinary Cancer Congress, 16th ECCO, 36th ESMO, 30th ESTRO Congress, Stockholm, September 2011.
20. American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, San Diego, CA, USA, February 2011.
21. 17th Panhellenic Congress of Clinical Oncology, Athens, March 2011.
22. 33rd Scientific Conference of Hellenic Society for Biological Sciences, Edessa, 2011.
23. ISE International Conference On Enzymes New Roles for Old Molecules: Enzymes in Personalized Medicine, Crete, Greece, 2010.
24. 8th Congress of the Balkan Union of Oncology, Sibiu, Romania, September 2010.
25. 16th Panhellenic Conference of Clinical Oncology , Athens, Greece, April, 2010.
26. 8th Tumor Markers - Targeted Therapy Congress, Athens, Greece, November 2010.
27. 9th Conference of the Greek Society of Clinical Chemistry, October 2010.
28. 16th Panhellenic Congress on Clinical Oncology, Athens, Greece, April 2010.
29. 36th Annual Panhellenic Conference on Medicine, Athens, May, 2010.
30. 32th Congress of the Hellenic Association of Biological Sciences, May, 2010.
31. 3rd World Congress on Controversies in Urology (CURy), Athens, Greece, February 2010.
32. 3rd International Symposium on Kallikreins and Kallikrein-Related peptidases, Munich, Germany, September 2009.
33. 7th International Symposium on Minimal Residual Cancer, September 2009, Athens, Greece.
34. Annual Meeting of the EORTC/NCI/ASCO on Molecular Markers in Cancer, Brussels, Belgium, October 2009.
35. 11th World Conference on Gastrointestinal Cancer, 24-27 June, 2009, Barcelona, Spain.
36. 15th Panhellenic Congress of Clinical Oncology, Athens, March 2009, (*1st poster prize*).
37. 60th Panhellenic Congress of the Hellenic Society of Biochemistry and Molecular Biology, Athens, November, 2009.
38. 34th FEBS Congress, Prague, Czech republic, July, 2009.
39. FEBS Advanced Lecture Course, Matrix Pathobiology, Signaling and Molecular Targets, Patras, Greece, 2009.
40. 33th FEBS Congress & 11th IUBMB Conference, Athens, July, 2008.
41. 27th International Congress of the International-Academy-of-Pathology, Athens Greece, October 2008.

42. 30^o Annual Conference of the Hellenic Society for Biological Sciences, Thessalonica, Greece, May 2008.
43. Apoptosis 2008 – From Mechanisms to applications, Luxembourg, January 2008.
44. 2st International Symposium on Kallikreins and Kallikrein Related Paptidases, Santorini, October 2007.
45. 5th meeting of International Proteolysis Society, Patras, Greece, October 2007.
46. 32th FEBS Congress, Vienna, Austria, Jule, 2007.
47. FEBS Advanced Lecture Course, Matrix Pathobiology, Signaling and Molecular Targets, Patras, Greece, 2007
48. American Association for Cancer Research Annual Meeting, Los Angeles, USA, April 2007.
49. 59th meeting of Hellenic Society of Biochemistry and Molecular Biology, Athens, November 2007.
50. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Prague, Czech Republic, Novber 2006.
51. 6^o Pan-Hellenic Symposium of Clinical Chemistry, Athens, Greece, November 2006.
52. 58th meeting of Hellenic Society of Biochemistry and Molecular Biology, Patras, November 2006.
53. 31th FEBS Congress, Istanbul, June, 2006.
54. American Association for Cancer Research Annual Meeting, Washington, USA, March 2006.
55. 23rd Winter School Meeting on Proteinases and their Inhibitors, Tiers, Germany, March 2006.
56. 6th European Molecular and Cellular Biology meeting: Cell Signaling World 2006: Signal Transduction Pathways as therapeutic targets, Luxembourg, January, 2006.
57. 28th Annual Conference of the Hellenic Society for Biological Sciences, Ioannina, Greece, May 2006.
58. 4th meeting of International Proteolysis Society LV5, Quebec City, Canada, October 2005.
59. 1st International Symposium on Kallikreins, Lausanne, September 2005.
60. 30th FEBS Congress - 9th IUBMB Conference, Budapest, Hungary, July 2005.
61. American Association for Cancer Research Annual Meeting, Anaheim, USA, March 2005.
62. American Society of Clinical Oncology (ASCO) Annual Meeting, USA, 2005.
63. 57th meeting of Hellenic Society of Biochemistry and Molecular Biology, Athens, November 2005.
64. 18th Congress of European Society for Urological Research, Athens, Greece, November 2004.
65. American Association for Cancer Research Annual Meeting, Orlando, USA, March 2004.
66. Seventh International Conference of Anticancer Research, Corfu, Greece, October 2004.
67. 12th ECDO Euroconference on Apoptosis, Chania, Crete, September 2004.
68. 12th United European Gastroenterology Week, (UEGW), September 2004.
69. Greek Association for Tumor Marker Annual Meeting , Athens, Greece, November 2004.
70. 3rd International Proteolysis Society meeting, Japan, November 2003.

71. 11th United European Gastroenterology meeting, Madrid, Spain, November 2003.
72. 2nd International Mediterranean Course in Mastology, Ioannina Greece, September 2004.
73. American Association for Cancer Research Annual Meeting, Washington DC, USA, July 2003.
74. 5th European Molecular and Cellular Biology meeting: APOPTOSIS 2003-From signaling pathways to therapeutic tools. Luxembourg, January 2003.
75. American Urology Association Annual Meeting, Chicago, IL, April 2003.
76. American Association of Clinical Chemistry Annual Meeting, Philadelphia, PA, July 2003.
77. 8th Mediterranean Congress of Urology, Crete, Greece, September 2003.
78. 7th Annual Winter Symposium of American Society of Clinical Oncology, 2003.
79. 2th Mediterranean Educational Breast Seminar, Ioannina, Greece, 2003.
80. 7th Pan Hellenic Conference of Psychosocial Oncology, Athens 2003.
81. American Association for Cancer Research Annual Meeting, San Francisco, USA, April 2002.
82. International Society of Fibrosis and Proteolysis annual meeting, Munich, Germany, September 2002.
83. American Society of Clinical Oncology annual Meeting, 2002.
84. Canadian Society of Laboratory Medicine, Annual Meeting, 2002.
85. American Association of Clinical Chemistry Annual Meeting, Orlando, USA, July 2002.
86. 4th Pan-Hellenic Conference of Tumor Biomarkers, Athens, Greece, 2002.
87. 6th Pan Hellenic Conference of Psychosocial Oncology, Athens 2002.
88. 19th Panhellenic Conference of Chemistry, Athens, March 2001.
89. 2th General Meeting of the International Proteolysis Society (IPS), Munich, Germany, November 2001.
90. 5th International Congress of the Hellenic Society for Breast Cancer Research (HSBCR), Athens, Greece, November 2001.
91. American Association of Clinical Chemistry Annual Meeting, Chicago, USA, July 2001.
92. American Association for Cancer Research Annual Meeting, New Orleans, USA, March 2001.
93. 18th Panhellenic Conference of Chemistry, Athens, March 2001.
94. Canadian Breast Cancer Research Society annual meeting, 2001.
95. Greek Association for Tumor Marker Annual Meeting , Athens, Greece, November 2000.
96. Greek Association of Clinical Chemistry Annual Meeting, Athens, Greece, November 2000.
97. 15th Panhellenic Urology Conference, Corfu, September, 2000.
98. American Association of Clinical Chemistry Annual Meeting, San Francisco, USA, July 2000.
99. The Endocrine Society Annual Meeting, Toronto, Canada, June 2000.
100. Canadian Association of Clinical Chemistry Annual Meeting, Hamilton, Canada, June 2000.
101. Annual Oak Ridge Conference of the American Association of Clinical Chemistry, Boston, US, May 2000.
102. American Association for Cancer Research Annual Meeting, San Francisco, USA, April 2000.

103. 1st AACR-NCI-EORTC International Conference, Washington, USA, November 1999.
104. American Association for Cancer Research Annual Meeting, Philadelphia, USA, April 1999.
105. American Association of Clinical Chemistry Annual Meeting, New Orleans, USA, July 1999.
106. The Endocrine Society Annual Meeting, San Diego, USA, June 1999.
107. 17th International Congress of Clinical Chemistry and Laboratory Medicine, Florence, Italy, June, 1999.
108. International Society for Enzymology Annual Meeting, Venice, Italy, June 1999.
109. Department of Pathology and Laboratory Medicine Annual Symposium on Advances in Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada, June 1999.
110. American Association of Cancer Research Annual Meeting, Philadelphia, USA, April 1999.
111. Annual Departmental Research Symposium in Laboratory Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada, February 1999.
112. European Respiratory Society Annual Congress, Geneva, Switzerland, September 1998.
113. American Association of Cancer Research and Acta Pathologica Microbiologica et Immunologica Scandinavica International Conference, Nyborg, Denmark, June 1998.
114. 2nd International Symposium Protease and Cancer of the Biomed-1-Program of the European Union. Nydorg, Denmark, June 1998.
115. Annual Greek Oral Pathology Conference, Thessaloniki, Greece, October 1998.
116. International Symposium Protease and Cancer of the Biomed-1-Program of the European Union and the Deutsche Forschungsgemeinschaft: German Cancer Research Center. Heidelberg, Germany, March 1997.
117. Annual Greek Oncology Conference, Athens, Greece, November 1997.
118. 21st Congress of the European Society for Medical Oncology: Vienna, Austria, November 1996.
119. Greek Association for Tumor Marker Annual Meeting, Athens, Greece, November 1996.
120. 3rd International Conference of the Mediterranean Society of Tumor Marker Oncology (MESTMO): Athens, Greece, October 1994.
121. Fourth International Conference of Anticancer Research, Rethymnon Crete, Greece, October 1992.

List of Publications

A. Original Research Papers

1. Rampias T, Vgenopoulou P, Avgeris M, Polyzos A, Stravodimos K, Valavanis C, **Scorilas A**, Klinakis A. A new tumor suppressor role for the Notch pathway in bladder cancer. *Nature Medicine.*; 20(10):1199-205, 2014 (IF=28.054).
2. Samaan S, Khella HW, Girgis A, **Scorilas A**, Lianidou E, Gabril M, Krylov SN, Jewett M, Bjarnason GA, El-Said H, Yousef GM. miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma. *J Mol Diagn.*, 2014 (IF= 3.955).
3. Papadopoulos EI, Fragoulis EG, **Scorilas A**. Human l-DOPA decarboxylase mRNA is a target of miR-145: A prediction to validation workflow. *Gene*; 554(2):174-180. 3, 2014 (IF= 2.082).
4. Tzovaras A, Kladi-Skandali A, Michaelidou K, Zografos GC, Missitzis I, Ardavanis A, **Scorilas A**. BCL2L12: A promising molecular prognostic biomarker in breast cancer. *Clin Biochem.*; 47(18):257-62, 2014 (IF=2.229).
5. Vakrakou A, Devetzi M, Papachristopoulou G, Malachias A, **Scorilas A**, Xynopoulos D, Talieri M. Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma. *Biol Chem.*; 395(9):1105-17, 2014 (IF =2.689).
6. Avgeris M, Stravodimos K, **Scorilas A**. Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. *Biol Chem.*; 395(9):1095-104, 2014 (IF =2.689).
7. Alexopoulou DK, Kontos CK, Christodoulou S, Papadopoulos IN, **Scorilas A**. KLK11 mRNA expression predicts poor disease-free and overall survival in colorectal adenocarcinoma patients. *Biomark Med*; 8(5):671-85, 2014 (IF =2.858).
8. Girgis H, Masui O, White NM, **Scorilas A**, Rotondo F, Seivwright A, Gabril M, Filter ER, Girgis AH, Bjarnason GA, Jewett MA, Evans A, Al-Haddad S, Siu KM, Yousef GM Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. *Mol Cancer.*; 13:101, 2014 (IF=5.397).
9. Pavlopoulou A, **Scorilas A**. A comprehensive phylogenetic and structural analysis of the carcinoembryonic antigen (CEA) gene family. *Genome Biol Evol*; 6(6):1314-26, 2014 (IF=4.532).
10. Foteinou E, Kontos CK, Giotakis AI, **Scorilas A**. Low mRNA expression levels of kallikrein-related peptidase 4 (KLK4) predict short-term relapse in patients with laryngeal squamous cell carcinoma. *Biol Chem.*;395(9):1051-62, 2014 (IF=2.689)
11. Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki CT, **Scorilas A**, Psyrris A. RAS/ PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. *Clin Cancer Res.* 20(11):2933-46, 2014 (I.F= 8.193).
12. Rapti SM, Kontos CK, Papadopoulos IN, **Scorilas A**. Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. *Clin Chem Lab Med.* 52(8):1217-27, 2014 (IF=2.955).
13. White NM, Masui O, Newsted D, **Scorilas A**, Romaschin AD, Bjarnason GA, Siu KW, Yousef GM. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. *Br J Cancer*; 110(5):1250-9, 2014 (IF= 4.817).

14. Christodoulou S, Alexopoulou DK, Kontos CK, **Scorilas A**, Papadopoulos IN. Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. *Tumour Biol*; 35(5):4673-85, 2014 (IF=2.840).
15. Theodorou M, Speletas M, Mamara A, Papachristopoulou G, Lazou V, **Scorilas A**, Katsantoni E. Identification of a STAT5 target gene, Dpf3, provides novel insights in chronic lymphocytic leukemia. *PLoS One*. Oct 14; 8(10):e76155, 2013 (IF=3.534).
16. Koumandou VL, **Scorilas A**. Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms. *PLoS One*; 8(7):e680742013, 2013 (IF=3.534).
17. Florou D, Patsis C, Ardavanis A, **Scorilas A**. Effect of doxorubicin, oxaliplatin and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells. *Cancer Biol Ther*; 14(7):587-96, 2013 (IF= 3.630).
18. Foutadakis S, Avgeris M, Tokas T, Stravodimos K, **Scorilas A**. Increased BCL2L12 expression predicts the short-term relapse of patients with TaT1 bladder cancer following transurethral resection of bladder tumors. *Urol Oncol*; 32(1):39.e29-36, 2013; (IF= 3.363).
19. Kontos CK, Fendri A, Khabir A, Mokdad-Gargouri R, **Scorilas A**. Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study. *BMC Cancer*.; 13:293, 2013 (IF = 3.319).
20. Avgeris M, Stravodimos K, Fragoulis EG, **Scorilas A**. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. *Br J Cancer*;108(12):2573-81, 2013 (IF= 4.817).
21. Mavridis K, Stravodimos K, **Scorilas A**. Quantified KLK15 Gene Expression Levels Discriminate Prostate Cancer From Benign Tumors and Constitute a Novel Independent Predictor of Disease Progression. *Prostate*;73(11):1191-201, 2013 (I.F= 3.566).
22. Michaelidou K, Tzovaras A, Missitzis I, Ardavanis A, **Scorilas A**. The expression of the CEACAM19 gene, a novel member of the CEA family, is associated with breast cancer progression. *Int J Oncol*.;42(5):1770-7, 2013 (IF= 2.773).
23. Alexopoulou DK, Papadopoulos IN, **Scorilas A**. Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer. *Clin Biochem*; 46(15):1453-61, 2013 (IF = 2.229).
24. Mavridis K, Stravodimos K, **Scorilas A**. Down-regulation and prognostic significance of microRNA 224 (miR-224) expression in prostate cancer. *Clin Chem*, 59(1):261-9, 2013 (I.F= 7.768).
25. Korbakis D, Fragoulis EG, **Scorilas A**. Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances. *Anti-Cancer Drugs*, 24(3):291-9, 2013 (I.F= 1.891).
26. Papachristopoulou G, Talieri M, **Scorilas A**. Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate. *Tumour Biol*, 34(1):369-78, 2013 (IF=2.840).
27. Karan-Djurasevic T, Palibrk V, Zukic B, Spasovski V, Glumac I, Colovic M, Colovic N, Jurisic V, **Scorilas A**, Pavlovic S, Tosic N. Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. *Med Oncol*. 30(1):405, 2013 (IF=2.058).

28. Lichner Z, **Scorilas A**, White NMA, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM. The Chromatin Remodeling Gene, *ARID1A* is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma. *Am J Pathol*, 2013 (I.F= 4.602).
29. Florou D, Papadopoulos IN, Fragoulis EG, **Scorilas A**. L-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients' survival with stomach adenocarcinomas. *J Cancer Res Clin Oncol*, 139(2):297-306, 2013. (IF = 3.009).
30. Devetzi M, Trangas T, **Scorilas A**, Xynopoulos D, Talieri M. Parallel overexpression and clinical significance of Kallikrein-related peptidases 7 and 14 (*KLK7 & KLK14*) in colon cancer. *Thromb Haemost*, 109(2), 2012. (I.F= 5.760).
31. Kontos CK, Chantzis D, Papadopoulos IN, **Scorilas A**. Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients. *Cancer Lett.*; 330(1):106-122, 2013 (I.F=5.016).
32. Geomela PA, Kontos CK, Yiotakis I, Fragoulis EG, **Scorilas A**. L-DOPA decarboxylase mRNA expression is associated with tumor stage and size in head and neck squamous cell carcinoma: a retrospective cohort study. *BMC Cancer*, 20,12(1):484, 2012 (IF = 3.319).
33. Florou D, Mavridis K, **Scorilas A**. The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. *Tumour Biol*, 33(6):2069-782012 (IF=2.840).
34. Patsis C, Glyka V, Yiotakis I, Fragoulis EG, **Scorilas A**. l-DOPA Decarboxylase (DDC) Expression Status as a Novel Molecular Tumor Marker for Diagnostic and Prognostic Purposes in Laryngeal Cancer. *Transl Oncol*, 5(4):288-96, 2012 (IF=2.558).
35. Geomela PA, Kontos CK, Yiotakis I, **Scorilas A**. Quantitative expression analysis of the apoptosis-related gene, BCL2L12, in head and neck squamous cell carcinoma. *J Oral Pathol Med*, 2012 (IF=1.870).
36. Thomadaki H, Floros KV, Pavlovic S, Tomic N, Gourgiotis D, Colovic M, **Scorilas A**. Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia. *Clin Biochem*, 45(16-17):1362-7, 2012 (IF=2.229).
37. Kontos CK, **Scorilas A**. Molecular cloning of novel alternatively spliced variants of BCL2L12, a new member of the BCL2 gene family, and their expression analysis in cancer cells. *Gene*, 505(1):153-66, 2012 (IF=2.082).
38. Faragalla H, Youssef YM, **Scorilas A**, Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A, Lichner Z, Bjarnason G, Sugar L, Attalah MI, Yousef GM. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. *J Mol Diagn*, 14(4):385-92, 2012 (IF=3.955).
39. Koutalellis G, Stravodimos K, Avgeris M, Mavridis K, **Scorilas A**, Lazaris A, Constantinides C. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer. *BJU Int*, 110(6 Pt B):267-73, 2012 (IF=3.130).
40. Thanopoulou E, Kotzamanis G, Pateras IS, Ziras N, Papalambros A, Mariolis-Sapsakos T, Sigala F, Johnson E, Kotsinas A, **Scorilas A**, Gorgoulis VG. The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer. *Tumour Biol*, 33(5):1429-36, 2012 (IF=2.840).
41. Talieri M, Zoma M, Devetzi M, **Scorilas A**, Ardavanis A. Kallikrein-related peptidase 6 (KLK6) gene expression in intracranial tumors. *Tumour Biol*, 33(5):1375-83, 2012 (IF=2.840).

42. Petraki C, Youssef YM, Dubinski W, Lichner Z, **Scorilas A**, Pasic MD, Komborozos V, Khalil B, Streutker C, Diamandis EP, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer. *Tumour Biol*, 33(4):1209-14, 2012 (IF=2.840).
43. Patsis C, Yiotakis I, **Scorilas A**. Diagnostic and prognostic significance of human kallikrein 11 (KLK11) mRNA expression levels in patients with laryngeal cancer. *Clin Biochem*, 45(9):623-30, 2012 (IF=2.229).
44. Evangelou I, Petraki C, Msaouel P, **Scorilas A**, Sdrolia E, Padazi G, Koborozos V, Koutsilieris M. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. *Eur J Clin Invest*, 42(7):777-83, 2012 (IF= 2.834).
45. Talieri M, Devetzi M, **Scorilas A**, Pappa E, Tsapralis N, Missitzis I, Ardavanis A. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact. *Tumour Biol*, 33(4):1075-84, 2012 (IF= 2.840).
46. Iakovlev VV, Gabril M, Dubinski W, **Scorilas A**, Youssef YM et al.. Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. *Lab Invest*, 92(1):46-56, 2012 (IF=3.828).
47. Petraki C, Dubinski W, **Scorilas A**, Saleh C, Pasic MD, Komborozos V, Khalil B, Gabril MY, Streutker C, Diamandis EP, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. *Pathol Res Pract*, 208(2):104-8, 2012 (IF=1.562).
48. Korbakis D, **Scorilas A**. Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. *Tumour Biol*, 33(3):865-75, 2012 (IF=2.840).
49. Avgeris M, Stravodimos K, **Scorilas A**. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance. *Prostate*, 71(16):1780-9, 2011 (I.F= 3.566).
50. Talieri M, Alexopoulou DK, **Scorilas A**, Kypraios D, Arnogiannaki N, Devetzi M, Patsavela M, Xynopoulos D Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. *Tumour Biol*, 32(4):737-44, 2011. (I.F=2.840).
51. Papageorgiou SG, Kontos CK, Pappa V, Thomadaki H, Kontsioti F, Dervenoulas J, Papageorgiou E, Economopoulos T, **Scorilas A**. The Novel Member of the BCL2 Gene Family, BCL2L12, Is Substantially Elevated in Chronic Lymphocytic Leukemia Patients, Supporting Its Value As a Significant Biomarker. *Oncologist*, 16(9):1280-91, 2011 (IF=4.540).
52. Dubinski W, Gabril M, Iakovlev VV, **Scorilas A**, Youssef YM et al. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. *Hum Pathol*, 43(7):1037-43, 2011 (IF=2.806).
53. Talieri M, Devetzi M, **Scorilas A**, Prezas P, Ardavanis A, Apostolaki A, Karameris A. Evaluation of kallikrein-related peptidase 5 expression and its significance for breast cancer patients: association with kallikrein-related peptidase 7 expression. *Anticancer Res*, 31(9):3093-100, 2011 (IF=1.872).
54. Avgeris M, Papachristopoulou G, Polychronis A, **Scorilas A**. Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. *Clin Proteomics*, 31,8(1):5, 2011. (New Journal).

55. Mathioudaki K, **Scorilas A**, Ardavanis A, Lymberi P, Tsiambas E, Devetzi M, Apostolaki A, Talieri M. Clinical evaluation of *PRMT1* gene expression in breast cancer. *Tumour Biol*, 32(3):575-82, 2011 (I.F=2.840).
56. Jamaspishvili T, **Scorilas A**, Kral M, Khomeriki I, Kurfurstova D, Kolar Z, Bouchal J. Immunohistochemical localization and analysis of kallikrein-related peptidase 7 and 11 expression in paired cancer and benign foci in prostate cancer patients. *Neoplasma*, 58(4):298-303, 2011 (IF=1.642).
57. Xinopoulos D, Bassioukas SP, Kypreos D, Korkolis D, **Scorilas A**, Mavridis K, Dimitroulopoulos D, Paraskevas E. Pancreatic duct guidewire placement for biliary cannulation in a single-session therapeutic ERCP. *World J Gastroenterol*, 17(15):1989-95, 2011 (IF= 2.433).
58. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, **Scorilas A**. *BCL2L12* is a Novel Biomarker for the Prediction of Short-term Relapse in Nasopharyngeal Carcinoma. *Mol Med.*, 17(3-4):163-71, 2011 (I.F= 4.824).
59. Thomadaki H, Lymberopoulou-Karaliota A, Maniatakou A, **Scorilas A**. Synthesis, spectroscopic study and anticancer activity of a water-soluble Nb(V) peroxo complex. *J Inorg Biochem*, 105(2):155-63, 2011 (I.F= 3.274).
60. Dorn J, Harbeck N, Kates R, Gkazepis A, **Scorilas A**, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. *Ann Oncol*, 22(4):877-83, 2011 (I.F= 6.578).
61. Papachristopoulou G, Avgeris M, Charlaftis A, **Scorilas A**. Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (*KLK14*) in malignant and benign breast tissues. *Thromb Haemost*, 105(1):131-7, 2011 (I.F= 5.760).
62. Xinopoulos D, Kypreos D, Bassioukas SP, Korkolis D, Mavridis K, **Scorilas A**, Dimitroulopoulos D, Loukou A, Paraskevas E. Comparative study of balloon and metal olive dilators for endoscopic management of benign anastomotic rectal strictures: clinical and cost-effectiveness outcomes. *Surg Endosc*, 25(3):756-63, 2010 (I.F=3.413).
63. Kontos CK, Papadopoulos IN, Fragoulis EG, **Scorilas A**. Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. *Br J Cancer*. 102(9):1384-90, 2010 (IF= 4.817).
64. Mavridis K, Avgeris M., Koutalellis G, Stravodimos K, **Scorilas A**. Expression analysis and study of the *KLK15* mRNA splice variants in prostate cancer and benign prostatic hyperplasia *Cancer Sci*, 101 (3):693 – 699, 2010 (IF= 3.534)
65. Psyrris A, Papageorgiou S, Liakata E, **Scorilas A**, Rontogianni D, Kontos CK, Argyriou Pectasides D, Pappa V, Kolialexi A, Economopoulos T. Phosphatidylinositol 3'-kinase catalytic subunit {alpha} gene amplification contributes to the pathogenesis of mantle cell lymphoma. *Clin Cancer Res*, 391(4):467-74. 2010 (I.F= 8.193).
66. Mavridis K, Talieri M, **Scorilas A**. *KLK5* gene expression is severely upregulated in androgen independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. *Biol Chem*, 391(4):467-74., 2010 (IF=2.689).
67. Florou D, Papadopoulos IN, **Scorilas A**. Molecular analysis and prognostic impact of the novel apoptotic gene *BCL2L12* in gastric cancer. *Biochem Biophys Res Commun*, 391(1):214-8, 2010 (IF=2.281).

68. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Ardavanis A, **Scorilas A**. Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. *Tumour Biol*, 31(5):391-9, 2010 (IF= 2.840).
69. Konstantoudakis G, Florou D, Mavridis K, Papadopoulos IN, **Scorilas A**. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. *Clin Biochem*, 43(15):1205-11, 2010 (I.F=2.229).
70. Chow TF, Mankaruos M, **Scorilas A**, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, Yousef GM. The miR-17-92 Cluster is Over Expressed in and Has an Oncogenic Effect on Renal Cell Carcinoma. *J Urol*, 183(2):743-51, 2010 (I.F=3.753).
71. Korbakis D, Gregorakis AK, **Scorilas A**. Quantitative analysis of human Kallikrein 5 (KLK5) expression in prostate needle biopsies: An independent cancer biomarker. *Clin Chem*, 55(5): 904-13, 2009 (I.F= 7.768).
72. Siu KW, DeSouza LV, **Scorilas A**, Romaschin AD, Honey RJ, Stewart R, Pace K, Youssef Y, Chow TF, Yousef GM. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. *J Proteome Res*, (8):3797-807, 2009 (I.F= 5.001).
73. Korbakis D, **Scorilas A**. Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene *BCL2L12*. *Tumour Biol*, 30(2):100-7, 2009 (I.F=2.840).
74. Talieri M, Mathioudaki K, Prezas P, Alexopoulou DK, Diamandis EP, Xynopoulos D, Ardavanis A, Arnogiannaki N, **Scorilas A**. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. *Thromb Haemost*, 101(4):741-7, 2009 (I.F= 5.760).
75. Thomadaki H, Floros KV, **Scorilas A**. Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member *BCL2L12*. *Ann N Y Acad Sci*, 1171:276-83, 2009 (I.F= 4.313).
76. Theophanous E, Petraki C, **Scorilas A**, Komborozos V, Veloudis G, Varga JL, Zarandi M, Schally AV, Koutsilieris M. The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. *Mol Med*, 15(7-8):242-7, 2009 (I.F= 4.824).
77. Emami N, **Scorilas A**, Soosaipillai A, Earle T, Mullen B, Diamandis EP. Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility. *Biol Chem*, 390(9):921-9., 2009 (I.F= 2.689).
78. Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, **Scorilas A**, Xynopoulos D, Diamandis EP. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. *Br J Cancer*, 100(10):1659-65, 2009 (IF= 4.817).
79. Kountourakis P, Psyrris A, **Scorilas A**, Markakis S, Kowalski D, Camp RL, Diamandis EP, Dimopoulos MA. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. *Thromb Haemostasis*, 101(3):541-6, 2009 (I.F=5.760).
80. Papachristopoulou G, Avgeris M, **Scorilas A**. Expression analysis and study of KLK4 in benign and malignant breast tumours. *Thromb Haemostasis*, 101 (2):381-7, 2009 (I.F=5.760).
81. Thomadaki H, Mavridis K, Talieri M, **Scorilas A**. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11. *Thromb Haemostasis*, 101(2):373-80, 2009 (I.F=5.760).

82. Devetzi M, **Scorilas A**, Tsiambas E, Sameni M, Fotiou S, Sloane BF, Talieri M. Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker. *Gynecol Oncol*, 112(3):531-6, 2009 (I.F=3.687).
83. Papadokostopoulou A, Mathioudaki K, **Scorilas A**, Xynopoulos D, Ardavanis A, Kouroumalis E, Talieri M. Colon cancer and protein arginine methyltransferase 1 gene expression. *Anticancer Res*, 29(4):1361-6, 2009 (IF= 1.872).
84. Thomadaki H, **Scorilas A**. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol. *Biol Chem*, 389(11):1427-34, 2008 (IF= 2.689).
85. Kontos CK, Papadopoulos IN, **Scorilas A**. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. *Biol Chem*, 389(12):1467-75, 2008 (IF= 2.689).
86. Thomadaki H, Karaliota A, Litos C, **Scorilas A**. Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu₂(L-carnitine)₂Cl₂(H₂O)₂]Cl₂, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines. *J Med Chem*, 51(13):3713-9, 2008 (I.F=5.480).
87. Mathioudaki K, Papadokostopoulou A, **Scorilas A**, Xynopoulos D, Agnanti N, Talieri M. The PRMT1 gene expression pattern in colon cancer. *Br J Cancer*, 16,99(12):2094-9,2008 (IF= 4.817).
88. Kountourakis P, Psyrris A, **Scorilas A**, Camp R, Markakis S, Kowalski D, Diamandis EP, Dimopoulos MA. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). *Cancer Sci*, 99(11):2224-9, 2008 (I.F=3.534).
89. Ardavanis A, Koumna S, Fragos I, Malliou S, Kyriakou F, Mantzaris I, **Scorilas A**, Rigatos G. Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity. *Anticancer Res*, 28(4C):2409-15, 2008 (IF= 1.872).
90. Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, **Scorilas A**, Baziotis N, Rigatos G. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. *Oncologist*, 13 (4):361-9, 2008 (I.F=4.540).
91. Psyrris A, Kountourakis P, **Scorilas A**, Markakis S, Camp R, Kowalski D, Diamandis EP, Dimopoulos MA. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. *Ann Oncol*, 19(7):1271-7, 2008 (I.F= 6.578).
92. Avgeris M, Koutalellis G, Fragoulis EG, **Scorilas A**. Expression Analysis and Clinical Utility of L-Dopa Decarboxylase (DDC) in Prostate Cancer. *Clin Biochem*, 41(14-15):1140-9, 2008 (I.F=2.229).
93. Thomadaki H, Tsiapalis CM, **Scorilas A**. The effect of the polyadenylation inhibitor cordycepin on human Molt-4 and Daudi leukaemia and lymphoma cell lines. *Cancer Chemother Pharmacol*, 61(4):703-11, 2008 (I.F = 2.571).
94. Gregorakis AK, Stefanakis S, Malovrouvas D, Petraki K, Gourgiotis D, **Scorilas A**. Total and free PSA kinetics in patients without prostate cancer undergoing radical cystoprostatectomy. *Prostate*, 68(7):759-65, 2008 (I.F=3.566).

95. Pampalakis G, **Scorilas A**, Sotiropoulou G. Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer. *Clin Biochem*, 41(7-8):591-7, 2008 (IF=2.229).
96. Thomadaki H, **Scorilas A**, Tsiapalis CM, Havredaki M. The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. *Cancer Chemother Pharmacol*, 61(2):251-65, 2008 (IF = 2.571).
97. Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A, Kardara E, Frangos I, Koumna S, Baziotis N, **Scorilas A**, Ardavanis A. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. *J Buon.*;13(3):409-13, 2008 (IF= 0.706).
98. Thomadaki H, **Scorilas A**. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. *Ann N Y Acad Sci*, 1095:35-44, 2007 (IF=4.313).
99. Katsarou ME, Thomadaki H, Katsaros N and **Scorilas A**. Effect of bleomycin and cisplatin on the expression profile of SRA1, a novel member of pre-mRNA splicing factors, in HL-60 human promyelocytic leukemia cells. *Biol Chem*, 388(8):773-8, 2007 (IF= 2.689).
100. Floros KV, Talieri M and **Scorilas A**. Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. *Biol Chem*, 387(12):1629-33,2007 (IF= 2.689).
101. Thomadaki H, Karaliota A, Litos C and **Scorilas A**. Enhanced Antileukemic Activity of the Novel Complex 2,5-Dihydroxybenzoate Molybdenum(VI) against 2,5-Dihydroxybenzoate, Polyoxometalate of Mo(VI), and Tetraphenylphosphonium in the Human HL-60 and K562 Leukemic Cell Lines. *J Med Chem*, 50(6):1316-21, 2007 (IF=5.480).
102. Floros KV, Thomadaki H, Florou D, Talieri M, **Scorilas A**. Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. *Ann N Y Acad Sci*, 1090:89-97, 2007 (IF=4.313).
103. Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, **Scorilas A**, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, Diamandis EP. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. *Clin Cancer Res*, 13(23):6984-92, 2007 (IF= 8.193)
104. Revelos K, Petraki C, **Scorilas A**, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. *Anticancer Res*, 27(5B):3651-60, 2007 (IF= 1.872).
105. Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, **Scorilas A**, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. *Gynecol Oncol*, 106(2):334-41, 2007 (IF=3.687).
106. Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, **Scorilas A**, Diamandis EP, Harbeck N. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. *Clin Cancer Res*, 13(6):1742-8, 2007 (IF= 8.193).
107. Shan SJ, **Scorilas A**, Katsaros D, Diamandis EP. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. *Br J Cancer*, 96(2):362-72, 2007 (IF= 4.817).
108. Efthimiadou EK, Thomadaki H, Sanakis Y, Raptopoulou CP, Katsaros N, **Scorilas A**, Karaliota A, Psomas G. Structure and biological properties of the copper(II) complex with the quinolone

- antibacterial drug N-propyl-norfloxacin and 2,2'-bipyridine. *J Inorg Biochem*, 101, 64-73, 2007 (I.F= 3.274).
109. Thomadaki H, Talieri M and **Scorilas A**. Prognostic value of the apoptosis related genes *BCL2* and *BCL2L12* in breast cancer. *Cancer Lett*, 247(1):48-55, 2007 (I.F=5.016).
 110. Prezas P, **Scorilas A**, Yfanti C, Viktorov P, Agnanti N, Diamandis E, Talieri M. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. *Biol Chem*, 387(12) :1607-12, 2006 (I.F= 2.689).
 111. Leoutsakou T, Talieri M and **Scorilas A**. Prognostic significance of the expression of SR-A1, encoding a novel SR-related CTD-associated factor, in breast cancer. *Biol Chem*, 387(12):1613-8, 2006 (I.F= 2.689).
 112. Ardavanis A, **Scorilas A**, Tryfonopoulos D, et al.. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. *Oncologist*, 11(6):563-73, 2006 (I.F=4.540).
 113. Shan SJ, **Scorilas A**, Katsaros D, Rigault de la Longrais I, Massobrio M, Diamandis EP. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. *Clin Chem*, 52(10):1879-86, 2006 (I.F= 7.768).
 114. Thomadaki H, Talieri M and **Scorilas A**. Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes *BCL2*, *BCL2L12*, *BAX*, *CASPASE-9* and *FAS*. *Biol Chem*, 387(8):1081-6, 2006 (I.F= 2.689).
 115. Leoutsakou T, Talieri M and **Scorilas A**. Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer. *Biochem Biophys Res Commun*,:344(2):667-74, 2006 (I.F=2.281).
 116. Agiamarnioti K, Triantis T, Papadopoulos K and **Scorilas A**. 10-(2-Biotinyloxyethyl)-9-acridone. A novel fluorescent label for (strept)avidin–biotin based assays. *J Photochem Photobiol A*, 181:126–131, 2006 (I.F=2.291).
 117. **Scorilas A** and Gregorakis AK. mRNA expression analysis of human kallikrein 11 (*KLK11*) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy. *Biol Chem*, 387(6):789-93, 2006 (I.F= 2.689).
 118. Thomadaki H, Tsiapalis CM and **Scorilas A**. Polyadenylate polymerase modulations in human epithelioid cervix and breast cancer cell lines, treated with etoposide or cordycepin, follow cell cycle rather than apoptosis induction. *Biol Chem*, 386(5):471-80, 2006 (I.F= 2.689).
 119. Slagter MH, **Scorilas A**, Gooren LJ, de Ronde W, Soosaipillai A, Giltay EJ, Paliouras M, Diamandis EP. Effect of Testosterone Administration on Serum and Urine Kallikrein Concentrations in Female-to-Male Transsexuals. *Clin Chem*, 52(8):1546-51, 2006 (I.F= 7.768).
 120. Borgono CA, Kishi T, **Scorilas A**, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. *Clin Cancer Res*,12: 1487-1493, 2006. (I.F= 8.193).
 121. Slagter MH, Gooren LJ, de Ronde W, Soosaipillai A, **Scorilas A**, Giltay EJ, Paliouras M, Diamandis EP. Serum and Urine Tissue Kallikrein Concentrations in Male-to-Female Transsexuals Treated with Antiandrogens and Estrogens. *Clin Chem*, 52: 1356-1365, 2006 (I.F= 7.768).

122. Slagter MH, Gooren LJ, **Scorilas A**, Petraki CD, Diamandis EP. Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals. *J Histochem Cytochem*, 54: 905-910, 2006 (I.F=2.403).
123. Oikonomopoulou K, **Scorilas A**, Michael IP, Grass L, Soosaipillai A, Rosen B, Murphy J, Diamandis EP. Kallikreins as markers of disseminated tumour cells in ovarian cancer-- a pilot study. *Tumour Biol*, 27(2):104-14, 2006 (I.F= 2.840).
124. Stavropoulou P, Gregorakis AK, Plebani M and **Scorilas A**. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. *Clin Chim Acta*, 357:190-5, 2005 (I.F=2.764).
125. **Scorilas A**, Agiamarnioti K, Papadopoulos K. Novel biotinylated acridinium derivatives: new reagents for fluorescence immunoassays and proteomics. *Clin Chim Acta*, 357:159-67, 2005 (I.F=2.764).
126. Katsarou ME, Papakyriakou A, Katsaros N and **Scorilas A**. Expression of the C-terminal domain of novel human SR-A1 protein: interaction with the CTD domain of RNA polymerase II. *Biochem Biophys Res Commun*, 334:61-8, 2005 (I.F=2.281).
127. Yannopoulos A, Dimitriadis E, **Scorilas A**, Trangas T, Markakis E, Talieri M. mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (*hTERT*) in intracranial tumours of patients in the island of Crete. *Br J Cancer*, 93:152-8,2005 (IF= 4.817).
128. Gregorakis AK, Malovrouvas D, Stefanakis S, Petraki K and **Scorilas A**. Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy. *Clin Chim Acta*, 357:196-201, 2005 (I.F=2.764).
129. Revelos K, Petraki C, Gregorakis A, **Scorilas A**, Papanastasiou P, Tenta R, Koutsilieris M. p27(kip1) and ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. *In Vivo*, 19:911-20, 2005 (I.F=1.148).
130. Ardavanis A, Tryfonopoulos D, Orfanos G, Karamouzis M, Scorilas A, Alexopoulos A, Rigatos G. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. *Onkologie*; 28(11):558-64, 2005. (IF=0.835)
131. Revelos K, Petraki C, Gregorakis A, **Scorilas A**, Papanastasiou P, Koutsilieris M. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. *Anticancer Res*, 25:3123-33, 2005 (IF= 1.872).
132. **Scorilas A**, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. *J Clin Oncol*, 22,678-85,2004 (I.F=17.879).
133. Floros KV, Thomadaki H, Katsaros N, Talieri M and **Scorilas A**. mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the *BCL2*-family, *BCL2L12*, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. *Biol Chem*, 385(11):1099-103,2004 (IF= 2.689).
134. Mathioudaki K, Leotsakou T, Papadokostopoulou A, Paraskevas E, Ardavanis A, Talieri M and **Scorilas A**. *SR-A1*, a member of the human pre-mRNA splicing factor family, and its expression in colon cancer progression. *Biol Chem*,385(9):785-90, 2004 (IF= 2.689).

135. Diamandis EP, Borgono CA, **Scorilas A**, Harbeck N, Dorn J, Schmitt M. Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. *Clin Biochem*, 37(9):823-9,2004 (I.F=2.229).
136. Talieri M, Diamandis EP, Gourgiotis D, Mathioudaki K, **Scorilas A**. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. *Thromb Haemost*, 91,180-6, 2004 (I.F=5.760).
137. Diamandis EP, **Scorilas A**, Kishi T, Blennow K, Luo LY, Soosaipillai A, Rademaker AW, Sjogren M. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. *Clin Biochem*,37,230-7,2004 (I.F=2.229).
138. Talieri M, Papadopoulou S, **Scorilas A**, Xynopoulos D, Arnogianaki N, Plataniotis G, Yotis J, Agnanti N. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. *Cancer Lett*, 205,97-106,2004 (I.F=5.016).
139. Mathioudaki K, **Scorilas A**, Papadokostopoulou A, Xynopoulos D, Arnogianaki N, Agnanti N, Talieri M. Expression analysis of *BCL2L12*, a new member of apoptosis-related genes, in colon cancer. *Biol Chem*.385(9):779-83, 2004 (IF= 2.689).
140. Stephan C, Yousef GM, **Scorilas A**, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. *J Urol*,171,187-91,2004 (I.F=3.753).
141. **Scorilas A**, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros D, Pagano F, Diamandis EP. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. *Prostate*, 54:220-229, 2003 (I.F=3.566).
142. **Scorilas A**, Chiang PM, Katsaros D, Yousef GM, Diamandis EP. Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. *Gene*, 310, 79-89, 2003 (I.F=2.082).
143. Floros KV, Thomadaki H, Lallas G, Katsaros N, Talieri M, **Scorilas A**. Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. *Ann N Y Acad Sci*, 1010,153-8,2003 (I.F=4.313).
144. Diamandis EP, Borgono CA, **Scorilas A**, Yousef GM, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. *Tumour Biol*, 24,299-309,2003 (I.F=2.840).
145. Talieri M, Diamandis EP, Katsaros N, Gourgiotis D, **Scorilas A**. Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. *Thromb Haemost*, 89:1081-8,2003 (I.F=5.760).
146. Stephan C, Yousef GM, **Scorilas A**, Jung K, Jung M, Kristiansen G, Hauptmann S, Bharaj BS, Nakamura T, Loening SA, Diamandis EP. Quantitative analysis of kallikrein 15 gene expression in prostatic tissue. *J Urol*, 169:361-364, 2003 (I.F=3.753).
147. Nakamura T, **Scorilas A**, Stephan C, Jung K, Soosaipillai AR, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. *Cancer Res*, 63, 6543-6546, 2003 (I.F=9.284).
148. Yousef GM, **Scorilas A**, Katsaros D, Fracchioli S, Iskander L, Borgono C, Puopolo M, Massobrio M, Diamandis EP. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. *J Clin Oncol*,21, 3119-3126, 2003. (I.F=17.879).

149. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, **Scorilas A**, Borgono C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Diamandis EP. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. *Cancer Res*, 63, 3958-3965, 2003. (I.F=9.284).
150. Yousef GM, Stephan C, **Scorilas A**, Ellatif MA, Jung K, Kristiansen G, Jung M, Polymeris ME, Diamandis EP. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. *Prostate*, 56, 287-292, 2003. (I.F=3.566).
151. Borgono CA, Fracchioli S, Yousef GM, Luo LY, Soosaipillai A, Puopolo M, Grass L, **Scorilas A**, Diamandis EP, Katsaros D. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. *Int J Cancer*, 106, 605-610, 2003. (I.F=5.007).
152. Kishi T, Grass L, Soosaipillai A, **Scorilas A**, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, Diamandis EP. Human kallikrein 8, a novel biomarker for ovarian carcinoma. *Cancer Res*, 63, 2771-2774, 2003. (I.F=9.284).
153. Nakamura T, Stephan C, **Scorilas A**, Yousef GM, Jung K, Diamandis EP. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. *Urology*, 61, 1042-1046, 2003 (I.F=2.132).
154. Yousef GM, Polymeris ME, Yacoub GM, **Scorilas A**, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, Diamandis EP. Parallel overexpression of seven kallikrein genes in ovarian cancer. *Cancer Res*, 63: 2223-2227, 2003. (I.F=9.284).
155. Yousef GM, Scorilas A, Nakamura T, Ellatif MA, Ponzzone R, Biglia N, Maggiorotto F, Roagna R, Sismondi P, Diamandis EP. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. *Breast Cancer Res Treat*, 78: 149-158, 2003 (I.F=4.198).
156. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, Diamandis EP. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. *Br J Cancer*, 88: 1101-1104, 2003 (IF= 4.817).
157. Diamandis EP, **Scorilas A**, Katsaros N, Stenman C, Henrik A, Soosaipillai A, Grass L, Katsaros D. Human kallikrein 6 (hK6): A new serum biomarker for diagnosis and prognosis of ovarian carcinoma. *J Clin Oncol*, 21, 1035-1043, 2003 (I.F=17.879).
158. Luo Y, Katsaros D, Scorilas A, Fracchioli S, Bellino R, Gramberen M, Bruijn H, Henrik A, Stenman U, Massobrio M, Zee A, Vergote I, Diamandis EP. The Diagnostic and Prognostic Value of Serum Human Kallikrein 10 in Ovarian Cancer. *Cancer Res*, 63, 807-811, 2003 (I.F=9.284).
159. Kyriakopoulou L, Yousef GM, **Scorilas A**, Katsaros D, Massobrio M, Fracchioli S, Diamandis EP. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. *Clin Biochem*, 36, 135-143, 2003 (I.F=2.229).
160. Yousef GM, Fracchioli S, **Scorilas A**, Borgoño C, Iskander L, Richiardi G, Massobrio M, Katsaros D, Diamandis EP. Steroid hormone regulation and prognostic value of the human Kallikrein gene 14 (KLK14) in ovarian cancer. *Am J Clin Pathol*, 119, 346-355, 2003 (I.F=3.005).
161. **Scorilas A**, Levesque AL, Ashworth KL, Diamandis E.P. Cloning, structural characterization, physical mapping and expression pattern of the human alpha-adaptin A gene. *Gene*, 289, 191-199, 2002 (I.F=2.082).
162. **Scorilas A**, Fotiou S, Tsiambas E, Yotis J, Kotsiandri F, Sameni M, Sloane BF, Talieri M. Determination of Cathepsin B expression may offer additional prognostic information for ovarian cancer patients. *Biol Chem*, 383:1297 – 1303, 2002 (IF= 2.689).

163. **Scorilas A**, Magklara A, Hoffman BR, Bromberg RM, Bjartell A and Diamandis EP. Highly sensitive array analysis using time resolved fluorescence and a novel streptavidin-based reagent. *Anal Sci*, 17: 547-550, 2002 (I.F=1.403).
164. Yousef GM, **Scorilas A**, Magklara A, Memari N, Ponzzone R, Sismondi P, Biglia N, Abd Ellatif M, Diamandis EP. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. *Br J Cancer*, 87: 1294-3000, 2002 (IF= 4.817).
165. Yousef GM, Borgono CA, **Scorilas A**, Ponzzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P, Diamandis EP. Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. *Br J Cancer*, 87: 1287-1293, 2002 (IF= 4.817).
166. Yousef GM, Obiezu CV, Jung K, Stephan C, **Scorilas A**, Diamandis EP. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. *Urology*, 60: 714-718, 2002 (I.F=2.132).
167. Zarghooni M, Soosaipillai A, Grass L, **Scorilas A**, Mirazimi N, Diamandis EP. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. *Clin Biochem*, 225-231, 2002 (I.F=2.229).
168. Chang A, Yousef GM, **Scorilas A**, Grass L, Sismondi P, Ponzzone R, Diamandis EP. Human Kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: An independent indicator of favorable prognosis in breast cancer. *Br J Cancer*, 86: 1457-1464, 2002 (IF= 4.817).
169. Hoffman BR, Katsaros D, **Scorilas A**, Diamandis P, Fracchioli S, Longrais IA, Colgan T, Puopolo M, Giardina G, Massobrio M, Diamandis EP. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. *Br J Cancer*, 23: 763-771, 2002 (IF= 4.817).
170. Obiezu CV, Soosaipillai A, Jung K, Stephan C, **Scorilas A**, Howarth DH, Diamandis EP. Detection of human Kallikrein 4 (hK4) in normal and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. *Clin Chem*, 48: 1232-1240, 2002 (I.F= 7.768).
171. Yousef GM, **Scorilas A**, Kyriakopoulou LG, Rendl L, Diamandis M, Ponzzone R, Biglia N, Giai M, Roagna R, Sismondi P, Diamandis EP. Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer. *Clin Chem*, 48: 1241-1250, 2002 (I.F= 7.768).
172. Yousef GM, **Scorilas A**, Chang A, Rendl L, Diamandis M, Jung K, Diamandis EP. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. *Prostate*, 51:126-132, 2002 (I.F=3.566).
173. Papadopoulou S, **Scorilas A**, Yotis J, Arnogianaki N, Plataniotis G, Agnanti N. Significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. *Tumour Biol*, 23: 170-178, 2002 (I.F=2.840).
174. **Scorilas A**, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M. Overexpression of matrix - metalloproteinase-9 in human breast cancer. A new favorable indicator in node-negative patients. *Br J Cancer*, 84: 1488-1496, 2001 (IF= 4.817).
175. **Scorilas A**, Kyriakopoulou L, Yousef GM, Ashworth L, Kwamie A, Diamandis E.P. Molecular cloning, physical mapping and expression analysis of a novel gene, BCL2L12, encoding for a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. *Genomics*, 72: 217-221, 2001 (I.F=2.793).

176. **Scorilas A**, Bharaj B, Giai M and Diamandis EP. Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer. *Br J Cancer*, 84: 760-767, 2001 (IF= 4.817).
177. **Scorilas A**, Yousef GM, Jung K, Meyts E, Carsten S, Diamandis EP. Identification and characterization of a novel human testis specific kinase substrate gene which is down-regulated in testicular carcinomas. *Biochem Biophys Res Commun*, 285: 400-408, 2001 (I.F.=2.281).
178. **Scorilas A**, Kyriakopoulou L, Katsaros D and Diamandis EP. Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of Pre-mRNA splicing factors: Overexpression in aggressive ovarian cancer. *Br J Cancer*, 85: 190-198, 2001 (IF= 4.817).
179. Obiezu CV, **Scorilas A**, Magklara A, Thornton MH, Wang CY, Stanczyk FZ, Diamandis EP. Prostate specific antigen (PSA) and human glandular kallikrein (hK2) are markedly elevated in polycystic ovary syndrome. *J Clin Endocr Metab* 86, 1558-1561, 2001 (I.F= 6.310).
180. Khosravi J, Diamandi A, Mistry J, **Scorilas A**. Insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 in benign prostatic hyperplasia and prostate cancer. *J Clin Endocr Metab*,86: 694-699, 2001 (I.F= 6.310).
181. Kim H, **Scorilas A**, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, Piccinno R, Gordini G, Diamandis EP. Human Kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. *Br J Cancer*, 84: 643-650, 2001 (IF= 4.817).
182. Magklara A, **Scorilas A**, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. *Clin Cancer Res*. 7: 806-811, 2001 (IF= 8.193).
183. Luo LY, Bunting P, **Scorilas A**, Diamandis EP. Human kallikrein 10: A novel tumor marker for ovarian carcinoma? *Clin Chim Acta*, 306: 111-118, 2001 (I.F=2.764).
184. Obiezu CV, **Scorilas A**, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, Diamandis EP. Higher kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. *Clin Cancer Res*, 7: 2380-2386, 2001 (IF= 8.193).
185. Luo LY, Katsaros D, **Scorilas A**, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, Diamandis EP. Prognostic Value of Human Kallikrein 10 Expression in Epithelial Ovarian Carcinoma. *Clin Cancer Res*, 7: 2372-2379, 2001 (IF= 8.193)
186. Yousef GM, **Scorilas A**, Jung K, Aschworth L and Diamandis EP. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. *J Biol Chem*, 276: 53-61, 2001 (I.F=4.600).
187. Papadopoulou S, **Scorilas A**, Arnogianaki N, Yotis J, Papapanayiotou B, Agnantis N, Talieri M. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa *Tumour Biol*, 22: 383-289, 2001 (I.F=2.840).
188. Yousef GM, Kyriakopoulou LG, **Scorilas A**, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. *Cancer Res*, 61: 7811-7818, 2001 (I.F=9.284).
189. Kalomenidis I, Orphanidou D, Papamichalis G, Vassilakopoulos T, **Skorilas A**, Rasidakis A, Papastamatiou H, Jordanoglou J, Roussos C. Combined expression of p53, Bcl-2, and p21WAF-1 proteins in lung cancer and premalignant lesions: association with clinical characteristics. *Lung*, 179: 265-278, 2001 (IF= 2.171)

190. **Scorilas A**, Talieri M, Ardavanis A, Curtis N, Yotis J, Dimitriadis E, Tsiapalis C and Trangas T. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer. *Cancer Res*, 60: 5427-5433, 2000 (I.F=9.284).
191. **Scorilas A**, Bjartell A, Lilja H, Moller C, Diamandis EP. Streptavidin-polyvinylamine conjugates labeled with a europium chelate: Applications in immunoassay, immunohistochemistry and microarrays. *Clin Chem*, 46: 1450-1455, 2000 (I.F= 7.768).
192. **Scorilas A**, Black MH, Talieri M, Diamandis EP. Genomic organization of the human protein arginine methyltransferase 1 gene (PRMT1): Differential expression of splice variants in breast cancer *Biochem Biophys Res Commun*, 278:349-259, 2000 (I.F=2.281).
193. **Scorilas A** and Diamandis EP. Polyvinylamine-streptavidin complexes labeled with a europium chelator - A universal detection reagent for solid-phase time resolved fluorometric applications. *Clin Biochem*, 33: 345-350, 2000 (I.F=2.229).
194. **Scorilas A**, Yu H, Soosaipilai A, Gregorakis A and Diamandis EP. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. *Clin Chim Acta*, 292: 127-138, 2000 (I.F=2.764).
195. Yousef GM, **Scorilas A** and Diamandis EP. Genomic organization, mapping, tissue expression and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. *Genomics*, 63: 88-96, 2000 (I.F=2.793).
196. Yousef GM, **Scorilas A**, Magklara A, Soosaipillai A and Diamandis E.P. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family - genomic characterization, mapping, tissue expression and hormonal regulation. *Gene*, 254: 119-128, 2000 (I.F=2.082).
197. Bharaj B, **Scorilas A**, Giai M and Diamandis EP. TA Repeat Polymorphism of the 5 α -Reductase Gene and Breast Cancer. *Cancer Epidem Biomar*, 6: 387-393, 2000 (I.F=4.324).
198. Nam R, Diamandis EP, Toi A, Trachtenberg J, Magklara A, **Scorilas A**, Papanastasiou P, Soosaipillai A, Jewett M and Narod S. Serum human glandular kallikrein (hK2) levels predict the presence of prostate cancer among men with moderately elevated prostate specific-antigen. *J Clin Oncol* , 5: 1036-1042, 2000 (I.F=17.879).
199. Sklavounou A, Chrysomali E, **Scorilas A**, Karameris A. TNF-a expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation. *J Oral Pathol Med*, 29: 370-375, 2000 (I.F=1.870).
200. Bharaj B, **Scorilas A**, Diamandis EP, Giai M, Levesque MA, Sutherland DJ, Hoffman BR. Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. *Breast Cancer Res Treat*, 61: 111-119, 2000 (I.F=4.198).
201. Obiezu CV, Giltay EJ, Magklara A, **Scorilas A**, Gooren LJ, Yu H, Howarth DJ, Diamandis EP. Dramatic suppression of serum prostate specific antigen and human glandular kallikrein by anti-androgens in male to female transsexuals. *J Urol*, 163: 802-805, 2000 (I.F=3.753).
202. Obiezu C, Giltay E, Magklara A, **Scorilas A**, Yu H, Gooren L and Diamandis EP. Serum prostate specific antigen is significantly elevated after testosterone administration in female to male transsexuals. *Clin Chem*, 46: 859-862, 2000 (I.F= 7.768).

203. Magklara A, **Scorilas A**, Stephan C, Kristiansen G, Hauptmann S, Jung K, Diamandis EP. Decreased concentrations of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant vs non-malignant prostatic tissue. *Urology*, 56: 527-532, 2000 (I.F.=2.132).
204. Yousef GM, Chang A, **Scorilas A**, Eleftherios P. Diamandis. Genomic organization of the human kallikrein locus on chromosome 19q13.3-q13.4. *Biochem Biophys Res Commun*, 276: 125-133, 2000 (I.F.=2.281).
205. **Scorilas A**, Trangas T, Yotis J, Pateras C, Talieri M. Determination of c-myc amplification and overexpression in breast cancer patients. Evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathologic characteristics using univariate and multivariate analysis. *Br J Cancer*, 81: 1385-1391, 1999 (IF= 4.817).
206. **Scorilas A**, Diamandis EP, Levesque MA, Papanastasiou-Diamandi A, Khosravi MJ, Gai M, Ponzone R, Roagna R, Sismondi P and Lopez-Otin C. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients. *Clin Cancer Res*, 5: 1778-1785, 1999 (IF= 8.193).
207. **Scorilas A**, Yotis I, Pateras CH, Trangas T, Talieri M. Predictive value c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. *Clin Cancer Res*, 5: 815-821, 1999 (IF= 8.193).
208. Magklara A, **Scorilas A**, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. *Clin Chem*, 45: 1960-1966, 1999 (I.F= 7.768).
209. Magklara A, **Scorilas A**, Lopez-Otin C, Vizoso F, Ruibal A, Diamandis EP. Human glandular kallikrein (hK2) in breast milk, amniotic fluid and breast cyst fluid. *Clin Chem*, 45, 1774-1780, 1999 (I.F= 7.768).
210. **Scorilas A**, Courtis N, Yotis J, Talieri M, Michailakis M, Trangas T. Poly(A)polymerase activity levels in breast tumor cytosols. *J Exp Clin Canc Res*, 17: 511-518, 1998 (I.F=3.271).
211. Ardavanis A, **Scorilas A**, Loukeri A, Gerakini F, Pissakas G, Missitzis I, Apostolikas N, Yiotis I. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence. *Anticancer Res*, 18: 2885-2890, 1998 (IF= 1.872).
212. Ardavanis A, Gerakini F, Amanatidou A, **Scorilas A**, Pateras C, Garoufali A, Pissakas G, Stravolemos K, Apostolikas N, Yiotis I. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: Inconsistency with their established prognostic significance. *Anticancer Res*, 17: 3665-3670, 1997 (IF= 1.872).
213. Ardavanis A, **Scorilas A**, Amanatidou A, Gerakini F, Missitzis I, Garoufali A, Pissakas G, Pateras C, Apostolikas N, Rigatos G and Yiotis I. Cathepsin-D concentration in tumour cytosols improves the accuracy of prognostic evaluation of primary breast cancer. *Anticancer Res*, 17: 1405-1410, 1997 (IF= 1.872).
214. **Scorilas A**, Yotis I, Stravolemos K, Gouriotis D, Keramopoulos A, Ampela K, Talieri M, Trangas T. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. *Anticancer Res*, 15: 1543-1548, 1995 (IF= 1.872).
215. **Scorilas A**, Yotis I, Gouriotis D, Keramopoulos A, Ampela K, Trangas T, Talieri M. Cathepsin-D and c-erbB-2 have an additive prognostic value for breast cancer patients. *Anticancer Res*, 13: 1895-1900, 1993 (IF= 1.872).

Reviews

216. **Scorilas A.**, Mavridis K. Predictions for the future of kallikrein-related peptidases in molecular diagnostics. *Expert Rev Mol Diagn* ;14(6):713-22, 2014 (IF=4.270).
217. Mavridis K, Avgeris M, **Scorilas A.** Targeting kallikrein-related peptidases in prostate cancer. *Expert Opin Ther Tar*;18(4):365-83, 2014 (I.F=4.130).
218. Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef GM, **Scorilas A**, Diamandis EP, Dorn J. Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. *Radiol Oncol.* 8;47(4):319-29, 2013 (IF=1.667).
219. Christodoulou MI, Kontos CK, Halabalaki M, Skaltsounis AL, **Scorilas A.** Nature Promises New Anticancer Agents: Interplay with the Apoptosis-related BCL2 Gene Family. *Anticancer Agents Med Chem*, 14(3):375-99, 2013 (IF=2.939).
220. Kontos CK, **Scorilas A**, Papavassiliou AG. The role of transcription factors in laboratory medicine. *Clin Chem Lab Med*; 51(8):1563-71, 2013 (IF=2.955).
221. Kontos CK, Christodoulou MI, **Scorilas A.** Apoptosis-related BCL2-family members: key players in chemotherapy. *Anticancer Agents Med Chem*, 2013 (IF= 2.939).
222. Kontos CK, Mavridis K, Talieri M, **Scorilas A.** Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: Mechanistic and clinical aspects. *Thromb Haemost*; 110(3):450-7, 2013 (I.F= 5.760).
223. Kontos CK, **Scorilas A.** Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers.. *Clin Chem Lab Med*, 50(11):1877-91, 2012 (IF= 2.955).
224. Avgeris M, Mavridis K, **Scorilas A.** Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. *Biol Chem*, 393(5):301-17, 2012 (IF=2.689).
225. Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, **Scorilas A.** The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. *Adv Hematol*, 2012:524308, 2012.
226. Avgeris M, Mavridis K, **Scorilas A.** Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. *Biol Chem*, 391(5):505-11 2010 (IF=2.689)
227. Mavridis K and **Scorilas A.** Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. *Future Oncol*, 6(2):269-85, 2010 (IF=2.611).
228. Thomadaki H, **Scorilas A.** Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. *Connect Tissue Res*, 49(3):261-4, 2008. (IF=1.982)
229. Thomadaki H and **Scorilas A.** BCL2 Family of apoptosis - related genes: Functions and clinical implications in cancer. *Crit Rev Cl Lab Sci*, 42:1-67, 2006 (I.F=7.000).
230. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, **Scorilas A**, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. *Biol Chem*, 387(6):637-41, 2006 (IF= 2.689).
231. Yousef GM, Obiezu CV, Luo LY, Magklara A, Borgono CA, Kishi T, Memari N, Michael P, Sidiropoulos M, Kurlender L, Economopolou K, Kapadia C, Komatsu N, Petraki C, Elliott M, **Scorilas A**, Katsaros D, Levesque MA, Diamandis EP. Human tissue kallikreins: from gene structure to function and clinical applications. *Adv Clin Chem*, 39:11-79,2005. (I.F= 4.302).

232. **Scorilas A.** Polyadenylate polymerase (PAP) and 3' end pre-mRNA processing: Function, assays and association to disease. *Crit Rev Cl Lab Sci*, 39:193-224, 2002 (I.F=7.000).

Editorials

233. Schmitt M, Renné T, **Scorilas A.** The kallikreins: old proteases with new clinical potentials. *Thromb Haemost.*;110(3), 2013 (I.F= 5.760).
234. **Scorilas A.** The effects of anticancer agents on cell apoptosis and on the expression of cancer-related genes. *Anticancer Agents Med Chem*, 2013 (IF= 2.939).
235. **Scorilas A**, Mavridis K, Magdolen V, Fritz H. Highlight: the 4th International Symposium on Kallikreins and Kallikrein-related peptidases. *Biol Chem*, 393(5):299-300, 2012 (IF=2.689).
236. **Scorilas A**, Mavridis K. Kallikrein-related peptidases (KLKs) as novel potential biomarkers in gastric cancer: An open yet challenging road lies ahead. *J Surg Oncol*, 105(3):223-4, 2012. (I.F= 2.843).

B. Original GenBank submissions

I. Genes

1. Kontos CK and **Scorilas A.** Homo sapiens BCL2L12 protein isoform 7 (*BCL2L12*) mRNA, complete cds, alternatively spliced. Accession # HM347053, 2010.
2. Kontos CK and **Scorilas A.** Homo sapiens *BCL2L12P1* pseudogene transcribed RNA, partial sequence. Accession # GQ202621, 2009.
3. Kontos CK and **Scorilas A.** Homo sapiens BCL2L12 variant 9 (*BCL2L12*) RNA, complete sequence, alternatively spliced. Accession # FJ868803, 2009.
4. Kontos CK and **Scorilas A.** Homo sapiens BCL2L12 variant 7 (*BCL2L12*) RNA, complete sequence, alternatively spliced. Accession # FJ868801, 2009.
5. Kontos CK and **Scorilas A.** Homo sapiens BCL2L12 variant 6 (*BCL2L12*) RNA, complete sequence, alternatively spliced. Accession # FJ868800, 2009.
6. Mathioudaki K, Talieri M. and **Scorilas A.** Homo sapiens protein arginine methyltransferase 1 isoform 4 (*HRMT1L2*) mRNA, complete cds, alternatively spliced. Accession # AY775289, 2004.
7. **Scorilas A** and Diamandis EP. Homo sapiens carcinoembryonic antigen-like proteins (*CEAL1*) gene, complete cds, alternatively spliced products. Accession # AF406955, 2003.
8. **Scorilas A** and Diamandis EP. Homo sapiens Bcl-2 related proline-rich protein (*BCL2L12*) gene, complete cds, alternatively spliced. Accession # AF289220, 2001.
9. **Scorilas A** and Katsaros D. Homo sapiens polynucleotide kinase-3'-phosphatase (*PNKP*) gene, complete cds. Accession # AF354258, 2001.
10. **Scorilas A**, Gourgiotis D, Scorila E, Iracleous DP, Katsaros N. Homo sapiens polynucleotide kinase-3'-phosphatase (*PNKP*) gene, promoter sequence and 5'UTR. Accession # AF533307, 2001.
11. **Scorilas A**, Yousef GM and Diamandis EP. Homo sapiens testis-specific kinase substrate (*TSKS*) gene, complete cds. Accession # AF200923, 2001.

12. **Scorilas A**, Black MH and Diamandis EP. Homo sapiens protein arginine N-methyltransferase 1 (HRMT1L2) gene, complete cds, alternatively spliced. Accession # AF222689, 2001.
13. **Scorilas A**, Yousef GM and Diamandis EP. Homo sapiens testis-specific kinase substrate (*TSKS*), mRNA. Accession # NM_021733, 2000.
14. **Scorilas A** and Diamandis EP. Homo sapiens ser/arg-rich pre-mRNA splicing factor SR-A1 (*SR-A1*) gene, complete cds. Accession # AF254411, 2000.
15. **Scorilas A** and Katsaros D. Human carnitine acyltransferase like 1 (*CATLI*) gene, alternative splice products, complete cds. #AF331918, 2000.
16. **Scorilas A** and Diamandis EP. Homo sapiens alpha-adaptin A related protein (AP2A1) gene, complete cds, alternatively spliced. Accession # AF289221, 2000.
17. Yousef GM, **Scorilas A** and Diamandis EP. Homo sapiens trypsin-like serine protease (*TLSP*) gene, complete cds. Accession # AF164623, 2000.
18. Yousef GM, Magklara A, **Scorilas A**. and Diamandis,E.P. Homo sapiens kallikrein 12 (*KLK11*), mRNA. Accession #NM_006853, 2000.
19. Yousef GM, **Scorilas A** and Diamandis EP. Homo sapiens stratum corneum chymotryptic enzyme gene, complete coding region. Accession # AF166330, 1999.
20. Yousef GM, **Scorilas A** and Diamandis EP. Homo sapiens trypsin-like serine protease (*TLSP*) gene, complete coding region. Accession # AF164623, 1999.

II. Proteins

21. Kontos CK and **Scorilas A**. BCL2L12 protein isoform 7. Accession # ADM35972, 2010.
22. Kontos CK and **Scorilas A**. BCL2L12 protein isoform 9. Accession # ACZ28452, 2009.
23. Kontos CK and **Scorilas A**. BCL2L12 protein isoform 8. Accession # ACZ28451, 2009.
24. Kontos CK and **Scorilas A**. BCL2L12 protein isoform 6. Accession # ACZ28450, 2009.
25. Kontos CK and **Scorilas A**. BCL2L12 protein isoform 5. Accession # ACZ28448, 2009.
26. Kontos CK and **Scorilas A**. BCL2L12 protein isoform 2. Accession # ACZ28445, 2009.
27. Kontos CK and **Scorilas A**. BCL2L12 protein isoform 4. Accession # ACZ28444, 2009.
28. Mathioudaki K, Talieri M. and **Scorilas A**. protein arginine methyltransferase 1 isoform 4 Accession # AAV41837, 2004.
29. **Scorilas A** and Diamandis EP. Carcinoembryonic antigen-like protein. Accession # AAP70003, 2003.
30. **Scorilas A** and Diamandis EP. carcinoembryonic antigen-like protein variant 1. Accession # AAP70002, 2003.
31. **Scorilas A** and Diamandis EP. Bcl-2 related proline-rich protein. Accession # AAG29495 2001.
32. **Scorilas A** and Diamandis EP. Bcl-2 related proline-rich protein-1. Accession # AAG29496, 2001.
33. **Scorilas A** and Katsaros D. Polynucleotide kinase-3'-phosphatase. Accession # AAK57340, 2001.
34. **Scorilas A**, Yousef GM and Diamandis EP. Testis-specific kinase substrate. Accession # AAF12819, 2001.

35. **Scorilas A**, Black MH and Diamandis EP. Protein arginine N-methyltransferase 1 (Interferon receptor 1-bound). Accession # Q99873, 2001.
36. **Scorilas A**, Black MH and Diamandis EP. Protein arginine N-methyltransferase 1-variant 1. Accession # AAF62895, 2001.
37. **Scorilas A**, Black MH and Diamandis EP. Protein arginine N-methyltransferase 1-variant 2. Accession # AAF62893, 2001.
38. **Scorilas A**, Black MH and Diamandis EP. Protein arginine N-methyltransferase 1-variant 3. Accession # AAF62894, 2001.
39. **Scorilas A** and Diamandis EP. Alpha-adaptin A related protein. Accession #AAL11040, 2001.
40. **Scorilas A** and Diamandis EP. Alpha-adaptin A related protein 1. Accession #AAL11039, 2001.
41. Yousef GM, **Scorilas A** and Diamandis EP. Kallikrein 7 precursor (Stratum corneum chymotrypsin enzyme; HSCCE). Accession # P49862, 2001.
42. Yousef GM, Magklara A, **Scorilas A** and Diamandis EP. Kallikrein 12 precursor (Kallikrein protein 5; KLK-L5). Accession # Q9UKR0, 2001.
43. **Scorilas A** and Diamandis EP. Ser/arg-rich pre-mRNA splicing factor SR-A1. Accession # AAF87552, 2000.
44. Yousef GM, **Scorilas A** and Diamandis EP. kallikrein 11 precursor (hippostatin) (trypsin-like protease). Accession # Q9UBX7,2000.
45. Yousef GM, **Scorilas A** and Diamandis EP. kallikrein 7 precursor (stratum corneum chymotryptic enzyme) Accession # P49862,2000.
46. Yousef GM, **Scorilas A** and Diamandis EP. Homo sapiens kallikrein 11 (KLK11), mRNA. Accession # NM_006853, 2000.
47. Yousef GM, **Scorilas A** and Diamandis EP. kallikrein 11; protease, serine, trypsin-like; protease, serine, 20. Accession # NP_006844, 2000.
48. Yousef GM, **Scorilas A** and Diamandis EP. Stratum corneum chymotryptic enzyme. Accession # AF166330_1, 2000.
49. Yousef GM, Magklara A, **Scorilas A**. and Diamandis,E.P. kallikrein 12. Accession # NP_062544, 2000.
50. Yousef GM, **Scorilas A** and Diamandis EP. Trypsin-like serine protease. Accession # AAD47815, 1999.

III. Review gene cards

51. Florou D, **Scorilas A**, Vassilacopoulou D, Fragoulis EG . DDC (dopa decarboxylase (aromatic L-amino acid decarboxylase). Atlas Genet Cytogenet Oncol Haematol. May 2011 .URL : <http://AtlasGeneticsOncology.org/Genes/DDCID50590ch7p12.html>
52. Kontos C, **Scorilas A** . SCAF1 (SR-related CTD-associated factor 1). Atlas Genet Cytogenet Oncol Haematol. March 2010 . URL : <http://AtlasGeneticsOncology.org/Genes/SCAF1ID46074ch19q13.html>
53. Thomadaki H, **Scorilas A** . BAX (BCL2-associated X protein). Atlas Genet Cytogenet Oncol Haematol. May 2009 . URL : <http://AtlasGeneticsOncology.org/Genes/BAXID128ch19q13.html>

54. Kontos C, Thomadaki H, **Scorilas A.** BCL2L12 (BCL2-like 12 (proline-rich)). Atlas Genet Cytogenet Oncol Haematol. August 2008.
URL : <http://AtlasGeneticsOncology.org/Genes/BCL2L12ID773ch19q13.html>

C. Abstracts in International Scientific Conferences

1. Mavridis K., Gueugnon F., Petit-Courty A., Courty Y., and **Scorilas A.** *CEACAM19*, the latest member of the CEACAM family of cancer-related cell adhesion molecules, represents a novel biomarker for lung cancer prognosis. FEBS-EMBO 2014, Paris, France, FEBS Journal 281 (Suppl. 1) (2014) pp442-443, 2014.
2. M. Avgeris, T. Tokas, K. Stravodimos, E. G. Fragoulis, **A. Scorilas.** Uncovering the dual clinical value of miR-143/145 cluster in bladder cancer epithelium and patients survival outcome, FEBS Journal 281 (Suppl. 1) (2014) pp275-276, 2014.
3. M.-I. Christodoulou, P. Samara, O. Tsitsilonis, E. Fragoulis, **A. Scorilas** Evidence for anti-proliferative properties of the anti-diabetic agent 1,1-dimethylbiguanide hydrochloride (metformin) on human ovarian cancer cells. FEBS-EMBO 2014, Paris, France, FEBS Journal 281 (Suppl. 1) (2014) pp 463-464, 2014.
4. Mavridis K., Michaelidou K., Welk A., Schmitt M., **Scorilas A.** Identification of miRNAs as novel biomarkers in the decision-making process for ovarian cancer management. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
5. Michaelidou K., Mavridis K., Kladi-Skandali A., Ardavanis A., **Scorilas A.** mRNA expression analysis of the tumor-related genes *KLK6*, *KLK8* and *KLK11* reveals their potential as prognostic biomarkers for breast cancer. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
6. I.K. Kyriakou, K. Mavridis, D. P. Kalogianni, P. C. Ioannou, T.K. Christopoulos, **A. Scorilas.** Development Of Ultrasensitive Molecular Methodology For The Identification And Evaluation Of New Molecular Markers For The Early Diagnosis, Prognosis And Monitoring Response To Therapy, Of Patients With Breast And Prostate Cancer. Proc XVI International Symposium of Luminescence Spectrometry, ISLS 2014, Rhodes, Greece, 2014
7. C.K. Kontos, **Scorilas A.** The use of next generation sequencing in biomarker discovery. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
8. M. Avgeris, T. Tokas, K. Stravodimos, E.G. Fragoulis, **A.Scorilas** Clinical significance of the tumor-suppressor miR-143/145 cluster in bladder cancer. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
9. S.Pavlovic, N. Tosic, **A. Scorilas** Molecular biomarkers in acute myeloid leukemia and chronic lymphocytic leukemia. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
10. P.G. Adamopoulos, C.K. Kontos, S. G. Papageorgiou, V. Pappa, and **A. Scorilas.** *KLKB1* mRNA overexpression possesses significant discriminatory value in chronic lymphocytic leukemia. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.

11. M. Christodoulou, P. Samara, O. Tsitsilonis, E. G. Fragoulis, A. Scorilas. The anti-diabetic agent 1,1-dimethylbiguanide hydrochloride (metformin) exerts anti-proliferative effect on human ovarian cancer cells. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
12. G. Papachristopoulou, E. Papadopoulos, A. Ardavanis, **A.Scorilas**. Upregulated miR-331 expression discriminates malignant from benign tumors: a promising indicator for differential diagnosis in breast cancer. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
13. A. Pavlopoulou, **A. Scorilas**. Molecular evolution and structural analysis of the carcinoembryonic antigen (CEA) family. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
14. E. Skourti, S. Logotheti, C. K. Kontos, I. P. Trougakos, I. Michalopoulos, **A. Scorilas**, V.Zoumpourlis. The functional role of miR-200 family miRNAs and miR-205 in the progression of the mouse skin carcinogenesis through downregulating specific oncogenes. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
15. L. Stamati, M. Avgeris, H. Kosmidis, M. Baka, T. Anastasiou, D. Piatopoulou, **A. Scorilas**, D.Gourgiotis. BCL2 and BAX expression as a novel predictor of childhood ALL patients' poor response to BFM treatment and early relapse. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
16. G. Vasileiadou, M. Avgeris, T. Tokas, K. Stravodimos, **A. Scorilas**. miR-193a-5p expression is deregulated in bladder tumors and serves as a novel tumor marker for the prediction of patients prognosis following treatment. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
17. G. Zervakis, M. Avgeris, T. Tokas, K. Stravodimos, **A. Scorilas**. Analysis of miR-1 expression in bladder cancer epithelium and assessment of its clinical value for the prediction of disease prognosis and patients' survival. Proc. International Conference Tumour biomarkers: From discovery to clinical applications, Anavyssos, Greece, 2014.
18. **A. Scorilas** Non-coding small RNAs as biological tumor markers. Proc. International Society of Enzymology Meeting (ISE 2014) , Kos, Greece, 2014.
19. P.G. Adamopoulos, C. K. Kontos, and **A. Scorilas**. Discovery of novel splice variants of the human carcinoembryonic antigen-related cell adhesion molecule 19 (CEACAM19) gene in cancer and leukemic cell lines, using next-generation (semi-conductor) sequencing. Proc. International Society of Enzymology Meeting (ISE 2014) , Kos, Greece, 2014.
20. M.Avgeris, A. Kladi-Skandali, D. Ghikas, E. Beletsiotis, K.Kalantzi, F. Gaitis, **A. Scorilas** Novel molecular assays for the sensitive and simultaneously detection of pathogens Salmonella spp., L. monocytogenes, E. coli O157:H7, G. stearothermofillus and their quality control. Proc. International Society of Enzymology Meeting (ISE 2014) , Kos, Greece, 2014
21. M. Christodoulou, E.Maratou, G. Pantoleon, C. Zorba, **A. Scorilas**, E. G. Fragoulis Study of the expression pattern of L-Dopa decarboxylase (DDC) in human β -pancreatic cells: indications of involvement in the insulin-biosynthesis pathway. Proc. International Society of Enzymology Meeting (ISE 2014) , Kos, Greece, 2014.

22. A. Kladi-Skandali, A. Ardavanis, **A.Scorilas**, D. Sideris. Overexpression of RNase κ is associated with markers of favorable prognosis in breast cancer . Proc. International Society of Enzymology Meeting (ISE 2014) , Kos, Greece, 2014.
23. G. Papachristopoulou, D. Florou, M.Talieri, **A. Scoriglas**. Breast cancer cells exposed to the anti-tumor effect of epirubicin, docetaxel or methotrexate distinctively modify the expression of BCL-2 family members as revealed by Real-time PCR and immunocytochemical analyses. Proc. International Society of Enzymology Meeting (ISE 2014) , Kos, Greece, 2014.
24. Michaelidou K., Mavridis K., Haritos C., Ardavanis A., **Scoriglas A**. KLK8 mRNA expression analysis in breast cancer: evaluation of its clinical significance. Proc. International Society of Enzymology Meeting (ISE), Kos, Greece, 2014.
25. Mavridis K., Stravodimos K., **Scoriglas A**. The miR-224-KLK15 axis in prostate tumors: Deregulation and prognostic significance. Proc, 64th Congress of the Hellenic Society of Biochemistry and Molecular Biology, pp17, Athens, Greece, 2013.
26. Adamopoulos P., Kontos C., Alexopoulou D., Rapti S.M., Papadopoulos I., **Scoriglas A**. Expression of miR-224, a novel molecular tissue biomarker predicting short-term relapse and poor overall survival in colorectal adenocarcinoma patients, is negatively correlated with mRNA levels of kallikrein-related peptidases 6 and 10. Proc, 64th Congress of the Hellenic Society of Biochemistry and Molecular Biology, pp48, Athens, Greece, 2013.
27. **A. Scoriglas** Prediction Of Prostate and Bladder Cancer Risk Based on KLK Gene-Targeted MicroRNAs. Proc. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp24, Toronto, Canada, 2013.
28. Michaelidou K., Kladi-Skandali A., Haritos C., Stamatopoulou S., Misitzis I., Ardavanis A. and **Scoriglas A**. KLK8 mRNA Expression Analysis in Breast Cancer: Downregulation In Cancerous Tissues and In Metastatic Disease 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp28-29, Toronto, Canada, 2013.
29. Mavridis K., Stravodimos K., **Scoriglas A**. microRNA 224: A Klk-Targeting mirna with Deregulated Expression and Promising Prognostic Value in Prostate Cancer. Proc. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp46, Toronto, Canada, 2013.
30. Avgeris M, Mavridis K., Stravodimos K., **Scoriglas A**. Downregulation of the KLK2- and KLK4-targeting miR-378a predicts short term relapse of prostate cancer patients. Proc. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp50, Toronto, Canada, 2013.
31. S.M. Rapti, C.K. Kontos, S. Christodoulou, I.N. Papadopoulos, **Scoriglas A**. miR-96: A Novel Molecular Tissue Biomarker Predicting Unfavorable Outcome In Colorectal Cancer Patients. Proc. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp45, Toronto, Canada, 2013.
32. C.K. Kontos, S.M. Rapti, S. Christodoulou, I.N. Papadopoulos, **Scoriglas A**. miR-34a Overexpression is a strong indicator of Unfavorable Survival Outcome In Colon Cancer Patients. Proc. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp45, Toronto, Canada, 2013.
33. D.K. Alexopoulou, C.K. Kontos, S. Christodoulou, I.N. Papadopoulos, **Scoriglas A**. Kallikrein-Related Peptidase 11 (KLK11) mRNA Expression Predicts Short-Term Relapse And Poor

- Overall Survival In Colorectal Cancer Patients. Proc. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp29, Toronto, Canada, 2013.
34. P. Adamopoulos, C.K. Kontos, S.M. Rapti, S. Christodoulou, I.N. Papadopoulos, **Scorilas A.** Enhanced miR-224 Transcription Predicts Short-Term Relapse And Poor Overall Survival In Colorectal Adenocarcinoma Patients. Proc. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp43, Toronto, Canada, 2013.
 35. Foteinou E., Kontos C.K., Yiotakis A.I., Yiotakis I., **Scorilas A.** Kallikrein-Related Peptidase 4 (KLK4) mRNA Expression: An Independent Favorable Prognosticator Of Head And Neck Squamous Cell Carcinoma Patients' Disease-Free Survival. Proc. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp44, Toronto, Canada, 2013.
 36. C.K. Kontos, D.K. Alexopoulou, S. Christodoulou, I.N. Papadopoulos, **Scorilas A.** Kallikrein-Related Peptidase 6 (KLK6) mRNA Expression: An Independent Unfavorable Prognosticator In Colon Cancer. 5th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2013), pp44, Toronto, Canada, 2013.
 37. **A. Scorilas.** Identification of novel biomarkers for breast Cancer and tumors of the female reproductive tract. Breast Cancer and tumors of the female reproductive tract meeting, Athens, December 2013.
 38. Foteinou E., Kontos C.K., Yiotakis A.I., Yiotakis I., **Scorilas A.** Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in head and neck squamous cell carcinoma patients. Ageing and Cancer cell biology: Convergent and divergent molecular mechanisms, Athens, 2013.
 39. Kontos C.K., Christodoulou M.I., Fragoulis E.G., **Scorilas A.** Quantification and study of the L-DOPA decarboxylase (DDC) mRNA expression in human colorectal adenocarcinoma cells treated with chemotherapeutic drugs. Ageing and Cancer cell biology: Convergent and divergent molecular mechanisms, Athens, 2013.
 40. Kontos C.K., Daskalaki S., Talieri M., **Scorilas A.** Molecular profile of key apoptosis-related BCL2-family genes including BCL2L12 in colorectal adenocarcinoma cells after treatment with chemotherapeutic agents. Ageing and Cancer cell biology: Convergent and divergent molecular mechanisms, Athens, 2013.
 41. Rapti S.M., Kontos C.K., Christodoulou S., Papadopoulos I.N., and **Scorilas A.** miR-34a, miR-96 and miR-182: novel molecular biomarkers with strong potential for the prediction of short-term relapse and overall survival in colorectal adenocarcinoma. Ageing and Cancer cell biology: Convergent and divergent molecular mechanisms, Athens, 2013.
 42. Skourti E., Logotheti S., Galtsidis S., Kritikos A., Xipolita M., Kontos C., **Scorilas A.**, Trougakos I. and Zoumpourlis V. Implication Of Mir-200 Family Mirnas And Mir-3069 In The Progression Of Mouse Skin Carcinogenesis. Ageing and Cancer cell biology: Convergent and divergent molecular mechanisms, Athens, 2013.
 43. K. Michaelidou, M. Avgeris, **A. Scorilas** and E. G. Fragoulis. L-DOPA decarboxylase (DDC) upregulation correlates with aggressive breast and prostate tumors, representing a novel biomarker for the accurate prognosis of breast and prostate cancer patients' outcome 38th FEBS congress, Saint Petersburg, Russia, July, 2013, *FEBS Journal 280 (Suppl. 1)* (2013) 3–617, pp 323, 2013.
 44. A. Kladi-Skandali, C.K. Kontos, A. Tzovaras, M. Talieri, I. Missitzis, A. Ardavanis, **A. Scorilas.** Expression of the BCL2-like 12 (BCL2L12) gene is associated with prolonged survival of breast

- adenocarcinoma patients, AACR proceedings, Abstract Number: LB-72, Washington, USA, 2013.
45. Mavridis K., Stravodimos K., **Scorilas A.** Quantitative analysis and evaluation of KLK15 classical mRNA transcript levels as a biomarker of disease progression in prostate cancer. *Proc Advances in Circulating Tumour Cells (ACTC 2012)*, P32, pp110, Athens, September 2012.
 46. Kontos C.K., Mavridis K and **Scorilas A.** Quantitative Expression Analysis And Study Of BCL2L12 And Other Members Of The BCL2 Apoptosis-Related Gene Family, As Promising Biomarkers For Monitoring Of Prostate And Colon Cancer Cellular Response To Chemotherapy. *Proc 22nd ETRS meeting*, pp 72, 4-5 October 2012, Athens, Greece, 2012.
 47. Kontos C.K., Thomadaki H., Mavridis K., Ardavanis A., and **Scorilas A.** Identification and molecular cloning of novel splicing variants of BCL2L12, a new member of the BCL2 family, and their expression analysis in breast, prostate, and colon cancer cells. *Proc. of the 103rd Annual Meeting of the American Association for Cancer Research*; Cancer Res 2012;72(8 Suppl):Abstract nr 2006, Chicago, IL. Philadelphia (PA): AACR; Mar 31-Apr 4, 2012.
 48. Papachristopoulou G., Florou D. and **Scorilas A.** Treatment of BT-20 cells with anticancer agents revealed alterations in the expression pattern of the apoptosis-related genes BAX, BCL2 and BCL2L12: new promising indicators for predicting chemotherapy response in breast cancer. P04-82. *Proc FEBS 2012, Seville, Spain, 2012 & FEBS Journal 279 (Suppl. 1) 52–576, pp 110, 2012.*
 49. Michaelidou K., Ardavanis A., Fragoulis E. G. and **Scorilas A.** Quantitative analysis and study of the mRNA expression of L-Dopa decarboxylase gene (DDC) in breast cancer. P28-9 *Proc FEBS 2012, Seville, Spain, 2012 & FEBS Journal 279 (Suppl. 1) 600–608, pp 602, 2012.*
 50. Mavridis K., Avgeris M., Stravodimos K. and **Scorilas A.** Expression analysis of miR-145 and miR-224 in prostate cancer: differential diagnostic and prognostic significance. P28-10, P28-9 *Proc FEBS 2012, Seville, Spain, 2012 & FEBS Journal 279 (Suppl. 1) 600–608, pp 602-603, 2012.*
 51. Kontos C., Chantzis D., Papadopoulos I., **Scorilas A.** Kallikrein-related peptidase 4 (KLK4) mRNA expression: a novel molecular tissue biomarker for the prediction of short-term relapse in colorectal adenocarcinoma. C-25, *Proc AACC 2012 & Clinical Chemistry, Vol. 58, No. 10, Supplement, pp A99, 2012(Awarded Poster).*
 52. Avgeris M., Stravodimos K., Fragoulis E. G., **Scorilas A.** miR-145 And Its Target, L-Dopa Decarboxylase (DDC), Are Promising Prognostic Biomarkers For The Disease-Free Survival of Prostate Cancer Patients C-27. *Proc AACC 2012 & Clinical Chemistry, Vol. 58, No. 10, Supplement, pp A100, 2012(Awarded Poster).*
 53. Devetzi M, Talieri M, Trangas T., **Scorilas A**, Poulakis A., Basioukas S., Kypraios D, Xynopoulos D. Clinical impact of human kallikrein-related peptidases 7 and 14 in colorectal cancer. OP085, UEGW 2011, *Gut 2011; 60(Suppl 3)*, Stockholm, October 2011.
 54. Tzovaras A., Mavridis K., Ardavanis A. and **Scorilas A.** Expression Analysis and Study of BCL2 and the Novel Member of the Apoptotic Genes BCL2L12, as Promising Biomarkers for Monitoring of Prostate Cancer Cells' Response to Chemotherapy. *European Multidisciplinary Cancer Congress, 16th ECCO, 36th ESMO, 30th ESTRO Congress*, Stockholm, *European Journal Of Cancer* Volume: 47 Supplement: 1 pp: S173-S173 , September 2011.
 55. Papachristopoulou G. Stamatopoulou S., Talieri M., Ardavanis A., **Scorilas A.** Study Of KLK4, KLK5 And KLK14 mRNA Levels In Breast Cancer Cells After Treatment With Antineoplastic

Agents. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, OP16, pp.48, September 2011.

56. Mavridis K., Stravodimos K., **Scorilas A.** Quantitative Analysis And Study Of The microRNA 224 (mir-224) And Its Target, *KLK15* Gene, In Prostate Tumors: Investigation Of Their Clinical Significance *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, OP18, pp.50, September 2011.
57. Avgeris M., Foutadakis S., Stravodimos K., **Scorilas A.** Quantification Of The Expression Of Kallikrein-Related Peptidase Gene (*KLK11*) Reveals Its Downregulation In Bladder Cancer Patients. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, OP22, pp.53, September 2011.
58. Kontos C. K., Chantzis D., Papadopoulos I. N., **Scorilas A.** *KLK4* mRNA Expression In Colon Cancer: A Novel Biomarker With Significant Prognostic Value. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, OP24, pp.54, September 2011.
59. Patsis C., Giotakis A., Yiotakis I., **Scorilas A.** Human Tissue Kallikrein-Related Peptidase 11 (*KLK11*) Expression Status As A Novel Biomarker For Laryngeal Cancer. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P06, pp.62, September 2011.
60. Karaliotas G. I., Mavridis K., **Scorilas A.**, Babis G. C. Expression Analysis Of The mRNA Levels Of Kallikrein-Related Peptidases In Human Osteoarthritis. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P23, pp.73, September 2011.
61. Tokas T., Avgeris M., Stravodimos K., Constantinides C. A., **Scorilas A.** Quantitative Expression Analysis Of Kallikrein-Related Peptidase 13 Gene (*KLK13*) In Bladder Cancer. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P26, pp.74-75, September 2011.
62. Linardoutsos D., Avgeris M., Bramis J., Zografos G.C., **Scorilas A.** Expression Analysis Of Kallikrein-Related Peptidase 4 Gene (*KLK4*) In Pancreatic Cancer. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P27, pp. 75, September 2011.
63. Papadopoulos E., Kyrikos V., Grigorakis A., Petraki C., **Scorilas A.** Clinical Evaluation Of The *KLK5* mRNA Levels In Kidney Cancer. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P28, pp. 76, September 2011.
64. Papadopoulou A., **Scorilas A.**, Kletsas D. Expression Of Kallikrein Genes In Senescent Human Fibroblasts. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P29, pp. 76-77, September 2011.
65. Devetzi M., Trangas T., **Scorilas A.**, Poulakis A., Katerinis P., Xynopoulos D., Apostolaki A., Talieri M. Human Kallikrein-Related Peptidase 14 (*KLK14*) Expression In Colorectal Cancer And Non-Cancer Tissues *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P30, pp. 77, September 2011.
66. Zoma M., **Scorilas A.**, Devetzi M., Talieri M. Expression And Clinical Evaluation Of Kallikrein-Related Peptidase 6 (*KLK6*) In Intracranial Tumors *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P31, pp. 77-78, September 2011.

67. Florou D., Mavridis K., **Scorilas A.** Exposure Of Gastric Cancer Cells To Various Antineoplastic Drugs Modifies *KLK13* mRNA Expression Levels. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P32, pp.78, September 2011.
68. Michaelidou K., Stefanopoulou P., Tzovaras A., Misitzis I., Ardavanis A., **Scorilas A.** Quantitative Expression Analysis And Clinical Evaluation OF *KLK6* In Breast Cancer. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P33, pp.79, September 2011.
69. Alexopoulou D. , Christodoulou S., Papadopoulos E., **Scorilas A.** Quantitative Expression Analysis Of *KLK10* And Evaluation Of Its Clinical Significance In Colorectal Cancer. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P35, pp.80, September 2011.
70. Avgeris M., Stravodimos K., Fragoulis E.G., **Scorilas A.** Correlated Expression Of The Kallikrein-Related Peptidase 4 (*KLK4*) And The L-Dopa Decarboxylase (*DDC*) Gene In Prostate Cancer Patients: Analysis Of Its Clinical Significance *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P36, pp.80, September 2011.
71. Kontos C.K., Klettas D., Toutouzas K., Ageli C., Katsargyris A., Klonaris C., **Scorilas A.** Expression Analysis Of Kallikrein-Related Peptidases In Human Carotid Atherosclerotic Lesions. *Proc. 4th International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK2011)*, Rhodes, Greece, P41, pp.84, September 2011.
72. Avgeris M., Stravodimos K., Fragoulis E.G., **Scorilas A.** L-dopa decarboxylase (*DDC*) gene overexpression contributes significantly in prostate cancer patients' prognosis *Proc. 36th FEBS Congress*, Volume: 278 Special Issue: SI Supplement: 1, Pages: 195-195, Torino (Turin), Italy, June 2011
73. Karaliotas G.I., Mavridis K., **Scorilas A.**, Babis G. mRNA expression Analysis Of *BCL2*, *BAX* And *BCL2L12* Apoptotic Genes In Osteoarthritis., *Proc.American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, San Diego, CA, USA, February 2011*, pp226, Poster No. P188, 2011.
74. Mavridis K., Thomadaki H., Talieri M., **Scorilas A.** Prostate Cancer Cells Respond to Mitoxantrone and Doxorubicin treatment by modulating the Expression Profiles of *BCL2* Apoptotic Family Genes and the kallikrein-related peptidase 5 (*KLK5*). *Proc International Society for Enzymology*, P.16, 2010.
75. Avgeris M., Korbakis D., Tokas T., Stravodimos K., **Scorilas A.** Expression profiles of the kallikrein-related peptidase 5 gene in prostate and bladder cancer: A new potential biomarker. *Proc International Society for Enzymology*, P.11, 2010.
76. **Scorilas A.** Novel Cancer biomarkers within the kallikrein gene locus on chromosome 19q13.3-q13.4. *Proc 8th Tumor Markers - Targeted Therapy Congress*, November 2010.
77. Mavridis K., Thomadaki H., Ardavanis A., **Scorilas A.** Treatment of androgen independent prostate cancer cells with methotrexate leads to apparent upregulation of the mRNA levels of Kallikrein genes *KLK5*, *KLK13* and *KLK15*. *Journal of BUON*, Vol.15, Supp1, OP58, pp20 September 2010.
78. Tzovaras A., Mavridis K., Thomadaki H., Doufexis D., Maliou S., Kountourakis P., Malamos N., Ardavanis A., **Scorilas A.** Molecular analysis and study of *BCL2* gene family members of the

apoptotic genes as promising biomarkers for monitoring breast, prostate and ovarian cancer cells' response to chemotherapy *Journal of BUON*, Vol.15, Supp1, OP55, pp20 September 2010.

79. Pavlovic S, Floros K, Thomadaki H, Tosic N, Gourgiotis D, Colovic M, **Scorilas A** Association Of High-Level Expression Of *BCL2L12* Gene With Adverse Outcome In Patients With Acute Myeloid Leukemia. *Haematologica-The Hematology Journal* Vol.95, pp.498-498, Suppl.2, June 2010.
80. Koutalellis G., Stravodimos K., Avgeris M., Mavridis K., **Scorilas A.**, Constantinedes C. Clinical and Molecular Differences Between Benign Prostate Hyperplasia and Prostate Cancer. *Proc.3rd World Congress on Controversies in Urology (CURy)*, Αθήνα, Φεβρουάριος 2010.
81. **Scorilas A.** Promising tumor biomarkers within the human tissue kallikrein gene locus on chromosome 19q13.3-q13.4 *Proc Int Symp Kallikreins: L10.3*, 2009.
82. Mavridis K, Talieri M, **Scorilas A.** Expression profiles of the *KLK5* and *KLK15* genes in the androgen independent prostate cancer cells after treatment with the anticancer agents mitoxantrone, doxorubicin and epirubicin *Proc Int Symp Kallikreins: L9.4*, 2009.
83. Avgeris M, Papachristopoulou G, Charlaftis A, **Scorilas A.** Clinical evaluation and study of the *KLK5* gene expression in malignant and benign breast lesions *Proc Int Symp Kallikreins: P02*, 2009.
84. Florou D, Konstantoudakis G, Mavridis K, Papadopoulos IN, **Scorilas A.** Quantitative analysis of *KLK13* mRNA expressional status and its clinical value in human primary gastric carcinomas *Proc Int Symp Kallikreins: P12*, 2009.
85. Kontos CK, Chantzis D, Papadopoulos IN, **Scorilas A.** Quantitative expression analysis and prognostic of *KLK4* mRNA expression in colon cancer *Proc Int Symp Kallikreins: P18*, 2009.
86. Mavridis K., Koutalellis G, Stravodimos K, **Scorilas A.** Quantitative analysis of the kallikrein-related peptidase 13 in prostate tumors *Proc Int Symp Kallikreins: P19*, 2009.
87. Michaelidou K, Kladi A, Ardavanis A, Zobolas V, **Scorilas A.** Expression analysis and study of the *KLK11* mRNA isoforms in cancerous and non cancerous breast tissues and in breast cancer cell lines *Proc Int Symp Kallikreins: P22*, 2009.
88. Papachristopoulou G, Avgeris M, , Charlaftis A, **Scorilas A.** The differential diagnostic value of the *KLK14* gene expression in breast tumors, *Proc Int Symp Kallikreins: P25*, 2009.
89. Dorn J , Harbeck N , Kates R , Gkazepis A , **Scorilas A.** Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B , Schmitt M. Expression differences of proteolytic factors uPA, PAI-1, and seven kallikrein-related peptidases (*KLK5*, 6, 7, 8, 10, 11, 13) between primary tumor and omentum metastasis impact outcome in advanced ovarian cancer. *EJC Supplements* 7 (4) : 16-17, 2009.
90. Mavridis K, **Scorilas A.** Treatment of prostate cancer cells with chemotherapeutic agents induces distinct alterations in the mRNA expression pattern of the kallikrein-related peptidases genes *KLK13* and *KLK15*. *Proc.1st International Conference on Molecular Cancer Research* O-24, 2009.
91. Mavridis K, **Scorilas A.** Preclinical evaluation of the novel Kallikrein genes *KLK13* and *KLK15* as new putative molecular markers for difeerencial diagnosis and suitable therapeutic handling of prostate cancer. *FEBS JOURNAL*, 69: 143-143, 2009.
92. Kontos C, Papadopoulos IN, Fragoulis EG, **Scorilas A.** mRNA Quantitative analysis and study of the L-Dopa decarboxylase (*DDC*) gene in colon cancer. *FEBS JOURNAL*, 276: 225-225, 2009.

93. Florou D., Papadopoulos I.N, **Scorilas A.** Clinical Strength of the L-Dopa Decarboxylase gene (DDC) in early detecting human gastric carcinomas *Proc Int Symp on Minimal Residual Cancer*, P16, 2009.
94. Florou D., Konstadoudakis G., Papadopoulos I.N, **Scorilas A.** Molecular profiles and study of the *BCL2L12* gene in stomach tumors and in gastric cells after treatment with prominent chemotherapeutic drugs *Annals of Oncology*, Vol.20, Supplement 7, 2009.
95. Petraki C, **Scorilas A**, Komborozos V, Veloudis G, Michalopoulou F, Sfikas C, Papanastasiou P and Diamandis EP. Immunohistochemical evaluation and prognostic significance of human tissue kallikrein 6 in colorectal cancer. *Histopathology*, 53: 155-155, 2008.
96. Petraki C, **Scorilas A**, Veloudis G, Komborozos V, Evangelou I, Papanastasiou P, Sfikas C, and Diamandis EP. The immunohistochemical expression of human tissue kallikrein 10 is an independent predictor for disease outcome in patients with colorectal cancer. *Histopathology*, 53, 156-156, 2008.
97. Geomela P, Glyka V, Yiotakis I, Fragoulis EG and **Scorilas A.** Expression analysis and study of L-Dopa Decarboxylase (*DDC*) in head and neck tumors. *FEBS JOURNAL*, 275, 122-122, 2008.
98. Liakata E, Kontos C, **Scorilas A**, Maratou E , Kontsioti F, Rontogianni D, Papageorgiou S, Pappa V, Pectasides D, Harhalakis N, Economopoulos T and Psyrris A. Increased copy numbers of the *PI3KCA* gene may contribute to the pathogenesis of mantle cell lymphoma. *FEBS JOURNAL* Volume: 275 Pages: 412-412, 2008.
99. Korbakis D and **Scorilas A.** Quantitative mRNA analysis of the apoptosis-related genes *BCL2* and *BCL2L12* in gastric cancer cells treated with anticancer drugs. *FEBS JOURNAL*, 275: 109-109, 2008.
100. Papachristopoulou G, Avgeris M, Polychronis A and **Scorilas A.** The novel member of the kallikrein gene family, *KLK4*, is overexpressed in breast tumours and significantly correlated with the apoptosis related genes *BCL2* and *BCL2L12* .*FEBS JOURNAL*, 275,129-129,2008.
101. Thomadaki H, Mavridis K and **Scorilas A.** BCL-2, BAX and BCL2L12 are modulated at the mRNA level in response of leukemic cells to the ABL protein tyrosine kinase inhibitor, Gleevec *FEBS JOURNAL*, 275: 110-110, 2008.
102. Kontos C, Papadopoulos IN, Fragoulis EG, Scorilas A. Prognostic significance of L-dopa decarboxylase (DDC) expression in colon cancer. *FEBS JOURNAL*, 275: 126-126, 2008.
103. Alexopoulou D, Scorilas A. Talieri M. The human-kallikrein related peptidase expression pattern in colorectal cancer. *FEBS JOURNAL*, 275: 372-372, 2008.
104. Mathioudaki K, Scorilas A, Talieri M. Expression pattern of protein arginine methyltransferase 1 gene (PRMT1) in breast and colon cancer. *FEBS JOURNAL*, 275: 414-414, 2008.
105. Kontos Ch, Papadopoulos I, Chantzis D and **Scorilas A.** The novel apoptosis-related gene, *BCL2L12*, is an independent and favorable prognostic marker for colon cancer. *Proc Am Assoc Cancer Res*, 2008.
106. Floros KV, Thomadaki H, Aller P and **Scorilas A.** Modulations, at the mRNA level, of apoptosis-associated genes, as a response of the acute myeloid leukemia cell line HL-60 to apoptosis induced by arsenic trioxide. *Apoptosis 2008 – From Mechanisms to applications*, PX4, 2008.
107. Thomadaki H, Floros KV and **Scorilas A.** mRNA expression analysis of the apoptosis-related genes BCL2, BAX, BCL2L12, CASPASE-3 and FAS in HL60 leukemia cells treated with taxol and vincristine. *Apoptosis 2008 – From Mechanisms to applications*, IX 58, 2008.

108. Avgeris M, Fragoulis EG, Stravodimos K, **Scorilas A**. Study of L-DOPA decarboxylase (*DDC*) in prostate tissues and cancer cell lines. *Proc 3rd Conf Diagnost Pred Exp Oncol*, P48, 2007.
109. Thomadaki H., Gourgiotis D., **Scorilas A**. Correlation of the molecular profile of the novel apoptosis-related gene, *BCL2L12*, with cancer cells sensitivity against distinct anticancer drugs *FEBS JOURNAL*, P59: 126-126, 2007.
110. Kontos Ch, Thomadaki H, Florou D, Avgeris M, Korbakis D and **Scorilas A**. Quantitative mRNA expression analysis and study of *BCL2L12*, a novel member of the apoptosis-related genes, in cancer cell lines. *Proc Int Prot Soc: P119*, 2007.
111. Kontos Ch, Papadopoulos I, Chantzis D and **Scorilas A**. The role of the novel apoptosis - related gene, *BCL2L12*, along colon cancer progression: a quantitative mRNA expression analysis. *Proc Int Prot Soc: P103*, 2007.
112. Avgeris M, Koutalellis G, Fragoulis EG, Stravodimos K, **Scorilas A**. Expression analysis and study of L-DOPA decarboxylase (*DDC*) in prostate cancer. *Proc Int Prot Soc*, 2007, P86.
113. Korbakis D and **Scorilas A**. mRNA expression analysis and study of *BCL2*, *BAX* and *BCL2L12* in gastric cancer cells after treatment with anticancer drugs. *Proc Int Prot Soc:P117*, 2007.
114. Florou D, Papadopoulos I, Konstantoudakis G, **Scorilas A**. Quantitative mRNA expression analysis and clinical evaluation of *BCL2L12*, a novel apoptosis-related gene, in gastric cancer with real-time PCR RT-PCR. *Proc Int Prot Soc: P345*, 2007.
115. Geomela P.A, Patsis C, Glyka V, Giotakis A, Giotakis I, **Scorilas A**, Expression analysis and study of the novel apoptosis-related gene, *BCL2L12*, in head and neck cancer. *Proc Int Prot Soc: P256*, 2007.
116. Thomadaki H, Mavridis K, Tsiapalis CM, Gourgiotis D and **Scorilas A**. Effect of Zn²⁺, a caspase regulator, on survival of U937 cells, a human histolytic lymphoma cell line: implication of polyadenylation. *Proc Int Prot Soc: P 291*, 2007.
117. Thomadaki H and **Scorilas A**. Identification of novel target genes as biomarkers for the assessment of cellular response to chemotherapy, in breast versus ovarian cancer cells: A molecular approach. *Proc Int Prot Soc: P104*, 2007.
118. Korbakis D, Gregorakis A.K, **Scorilas A**. Expression analysis and study of the differential diagnostic potential of kallikreins 5 and 7 in prostate cancer after needle prostate biopsy. *Proc Int Symp Kallikreins: P41*, 2007.
119. Avgeris M, Koutalellis G, Stravodimos K, **Scorilas A**, Expression analysis and study of *KLK4* in prostate cancer. *Proc Int Symp Kallikreins: P42*, 2007.
120. Avgeris M, Mavridis K, Thomadaki H, Kontos Ch, Avzioti K, Papalexis P, **Scorilas A**. Expression analysis of the genes *KLK4* and *KLK15* in cancer cell lines. *Proc Int Symp Kallikreins: P43*, 2007.
121. Mavridis K, Avgeris M, Koutalellis G, Stravodimos K, **Scorilas A**. Clinical evaluation of the *KLK15* mRNA spliced variants in prostate tumors. *Proc Int Symp Kallikreins: P44*, 2007.
122. Papachristopoulou G, Avgeris M, **Scorilas A**. Expression analysis and study of *KLK4* and *BCL2L12* in benign and malignant breast tumors. *Proc Int Symp Kallikreins: P45*, 2007.
123. Thomadaki H, Mavridis K, Talieri M, **Scorilas A**. Kallikreins 11 and 15 are new putative molecular markers for suitable therapeutic handling of prostate cancer. *Proc Int Symp Kallikreins: P46*, 2007.

124. Toubanaki DK, Kontos Ch, Fragoulis EG, Christopoulos TK, **Scorilas A**. Development and validation of an RNA-based quantitative method for the determination of L-DOPA decarboxylase (DDC) at the mRNA level. *Proc Instrumental Methods of Analysis – Modern Trends and Applications*: P260, 2007.
125. Kontos Ch, Toubanaki DK, Fragoulis EG, Christopoulos TK, **Scorilas A**. Quantitative analysis and study of L-Dopa Decarboxylase in cancer cells using real time and competitive RT-PCR assays. *FEBS Letters*: 1021PT, 2007.
126. Kontos Ch, Papadopoulos I, Chantzis D and **Scorilas A**. Expression Analysis and Prognostic Significance of the *BCL2L12*, a New Member of the Apoptosis Related Genes, in Colon Cancer. *Proc Am Assoc Cancer Res*: 1769, 2007.
127. Thomadaki H, Gourgiotis D and **Scorilas A**. The effect of antitumour agents on the mRNA expression of the apoptosis-related genes in human leukaemic cells. *FEBS Advanced Lecture Course on Matrix Pathobiology, Signaling and Molecular Targets*: P 256, 2007.
128. Thomadaki H and Scorilas A. Cancer cells' response to chemotherapeutic drugs action: a molecular approach. *Proc 9th Annual HRCCTMB Meeting*: 16, 2007.
129. Scorilas A. Kallikreins as novel molecular biomarkers for diagnosis and prognosis of hormonal – related cancers. *Proc 3rd Conference on Diagnostic, Predictive and Experimental Oncology*, 17, 2007.
130. Thomadaki H, Talieri M, Ardavanis A and **Scorilas A**. The role of the novel apoptosis related gene *BCL2L12* in prognosis and individualized treatment of breast cancer: A molecular and clinical approach. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. *Proc AACR-NCI-EORTC*: 142, 2006.
131. Leoutsakou T, Talieri M, Christopoulos Th and **Scorilas A**. mRNA expression profiling of anticancer drugs and hormonals-treated human breast and ovarian cancer cells reveals distinct modulations of the novel splicing-related gene SRA1. *Proc Am Assoc Cancer Res*: LBA-8753, 2006.
132. Thomadaki H, Gourgiotis D, Kosmidis VH and **Scorilas A**. The effect of antitumour agents on the mRNA expression of the apoptosis-related genes in human leukaemic cells. *FEBS Letters*: 1659, 2006.
133. Thomadaki H, Ardavanis A, Talieri M and **Scorilas A**. Anticancer drug-treated of breast and ovarian cancer cells reveals distinct modulations in expression of apoptosis genes. *FEBS Letters*: 1659, 2006.
134. Kontos Ch, Fragoulis EG and **Scorilas A**. Expression analysis of L-Dopa Decarboxylase in human cancer cell lines using RT-PCR and quantitative real time RT-PCR. *FEBS Letters*: 1634, 2006.
135. Thomadaki H, Talieri M and **Scorilas A**. Distinct alterations in the expression levels of SRA1 gene, in the breast cancer cell line MCF7, as a response to treatment with anticancer drugs. *Proc Int Soc Fibrinol Prot*: 312, 2006.
136. Floros KV, Thomadaki H, Sonja P, Talieri M, Milica C, Gourgiotis D and **Scorilas A**. Real-time PCR analysis of *BCL2L12*, a novel member of *BCL2* family of the apoptosis-related genes, in human leukemia. *Proc Int Soc Fibrinol Prot*: 316, 2006.
137. **Scorilas A**. The tissue kallikrein family of serine proteases: genomic organization, tissue-specific expression, physiologic roles and applications in cancer. *Proc 8th Annual Meeting of the Hellenic Research Club for Connective Tissue & Matrix Biology*, 6, 2006.

138. Thomadaki T and **Scorilas A**. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin and doxorubicin, at the mRNA expression levels of distinct apoptosis-related genes, including the new member, *BCL2L12*. *Proc Cell Signaling World 2006 meeting*: X 96,2006.
139. Floros KV, Thomadaki H, Florou D, Talieri M and **Scorilas A**. Alterations in the mRNA expression of the novel, apoptosis-related gene, *BCL2L12*, after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. *Proc Cell Signaling World 2006 meeting*: X 30, 2006.
140. Kountourakis P, Psyrris A, **Scorilas A**, Kowalski D, Camp R, Markakis S, Dimopoulos M. Prognostic significance of human kallikrein 7 protein expression levels in ovarian cancer by using automated quantitative analysis. *Therapeutics. Proc AACR-NCI-EORTC*: 326, 2006.
141. Alexopoulou D, **Scorilas A**, Skoufalas P, Xynopoulos D, Talieri M. Significance and clinical evaluation of human kallikrein 6 (KLK6) expression in colon cancer. *Proc Am Assoc Cancer Res*: 398, 2006.
142. Shan S, **Scorilas A**, Soosaipillai A, Katsaros D, Rigault I, Puopolo M, Diamandis EP. Human tissue kallikrein 7 over-expression in ovarian carcinoma: a novel marker of unfavorable prognosis. *Proc Am Assoc Cancer Res*: 4503, 2006.
143. Alexopoulou A, Scoufalas P, **Scorilas A**, Xynopoulos D, Talieri M. Significance and clinical evaluation of human kallikrein gene 6 (KLK6) mRNA expression in colon cancer. *Proc Winter School Meeting on Proteinases and their Inhibitors*: 13, 2006.
144. Floros KV, Talieri M and **Scorilas A**. Expression analysis and study of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, *BCL2L12*, in HL-60 human promyelocytic leukemia cells after treatment with Cisplatin and Topotecan. *Proc Int Prot Soc*: PIII 14,2005.
145. Prezas P, Mathioudaki K, Papadokostopoulou A, Xynopoulos D, Arnogiannaki N, **Scorilas A**, Talieri M. Clinical implication of KLK7 in colon cancer. *Proc Int Prot Soc*: LV5, 2005.
146. Thomadaki H, Talieri M, **Scorilas A**. Distinct alterations in the expression levels of BCL2 family genes, including the new member *BCL2L12*, in the breast cancer cell line MCF-7, as a response to treatment with anticancer drugs. *Proc Int Prot Soc*: PI 77, 2005.
147. Schmalfeldt B, Kates R, Dorn J, **Scorilas A**, Grass L, Soosaipillai A, Diamandis EP, Kiechle M, Schmitt M, Harbeck N. Impact of proteolytic factors on surgical success and survival in ovarian cancer. *Proc ASCO*: #5068,471,2005.
148. Schmitt M, Kates R, Dorn J, **Scorilas A**, Grass L, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Harbeck N. Impact of proteolytic factors (uPA, PAI-I, tissue kallikreins) on surgical success and survival in ovarian cancer. *Thromb Haemost*: 93:A24,2005.
149. Talieri M, **Scorilas A**, Yotis J, Devetsi M, Fotiou S, Tsiambas E, Kotsiandri F, Sameni M, Sloane BF. Immunohistochemical analysis of cathepsin B in endometrial cancer. *Proc Int Prot Soc*: PI 78, 2005.
150. Leoutsakou Th, Talieri M, Yotis J, Ardavanis A, **Scorilas A**. Prognostic significance of the expression of *SR-A1* gene, encoding for a new member of the human ser-arg-rich family of pre-mRNA splicing factors, in breast cancer. *Proc Int Prot Soc*: PI 75, 2005.
151. Thomadaki H, Ardavanis A, Talieri M, Kletsas D and **Scorilas A**. Prognostic significance of *BCL2L12*, a new member of the *BCL2* family of apoptosis-related genes, in breast cancer. *FEBS Letters*: A4-066P, 2005.

152. Skoufalis P, Yfanti C, **Scorilas A**, Talieri M., Expression and clinical evaluation of KLK6, KLK7 and KLK8 in intracranial tumors. *Proc Int Symp Kallikreins: 71*, 2005.
153. Economopoulou K, **Scorilas A**, Grass L, Soosaipillai A, Rosen B, Murphy J, Diamandis EP. Kallikreins as markers of disseminated tumour cells in ovarian cancer. *Proc Am Assoc Cancer Res: 4878*, 2005.
154. Leoutsakou T, Talieri M, Mathioudaki K, Stavropoulou P, Arnogianaki N, Diamandis EP, **Scorilas A**. Expression analysis and prognostic significance of SR-A1 gene, encoding for a new member of the human ser/arg-rich family of pre-mRNA splicing factors, in breast and ovarian cancer. *Proc Am Assoc Cancer Res: 1899*, 2005.
155. Petraki C, Veloudis G, Komborozos V, **Scorilas A**, Papanastasiou P, Diamandis EP. Immunohistochemical evaluation and prognostic significance of human kallikreins 6 and 10 in colorectal cancer. *Proc Am Assoc Cancer Res: 1260*, 2005.
156. Dorn J, Harbeck N, Kates R, **Scorilas A**, Grass L, Soosaipillai A, Diamandis EP, Schmitt M. Analysis of the differential expression of proteolytic factors uPA, PAI-1, and seven tissue kallikreins (hk5,6,7,8,10,11,13) between primary ovarian carcinoma tissues and corresponding omentum metastases. *Proc Am Assoc Cancer Res: 2972*, 2005.
157. Mathioudaki K, Papadokostopoulou A, Xynopoulos D, Arnogianaki N, Agnanti N, **Scorilas A**, Talieri M. Expression analysis of KLK7 gene in colon cancer. *Proc 12th UEGW, Gut* , 2004.
158. **Scorilas A**, Mathioudaki K, Leoutsakou T, Arnaouti M, Diamandis EP, Talieri M. Expression analysis of the SR-A1 gene, encoding for a novel member of the human Ser/Arg-rich family of proteins, in breast cancer. *Proc Am Assoc Cancer Res: 1728*, 2004.
159. Borgono CA, Kishi T, **Scorilas A**, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP. Human kallikrein 8 protein (hK8) in ovarian cancer cytosols: A new marker of favorable prognosis. *Proc Am Assoc Cancer Res: 4444*, 2004.
160. Thomadaki H, **Scorilas A**, Tsiapalis CM. Commencement or inhibition of drug-induced apoptosis, via regulation of polyadenylation, is cell type specific. *Proc 12th ECDO Euroconference on Apoptosis: P-163*, 2004.
161. Floros KV, Thomadaki H, Katsaros N, Talieri M, **Scorilas A**. Alterations in the expression levels of BCL2, BAX, FAS, Caspase9, Caspase3 and BCL2L12, a new member of the BCL2 family, in response to drug-induced apoptosis. *Proc 12th ECDO Euroconference on Apoptosis: P-51*, 2004.
162. Yousef G, Polymeris ME, Yacoub GM, Fracchioli S, **Scorilas A**, Soosaipillai A, Katsaros D, Diamandis EP. In silico analysis of kallikrein gene expression in ovarian cancer. *Proc Am Assoc Cancer Res:4461*, 2004.
163. Gregorakis A, Papanastasiou P, Borousas D, Bharaj B, Petraki C, **Scorilas A**, Diamandis EP. Thymine - Adenine (TA) repeat polymorphism of the 5a - reductase gene (SRD5A2) and prostate cancer risk. *Proc Eur Soc Urol Res: PSI.8*, 2004.
164. Papanastasiou P, Gregorakis A, Borousas D, Bharaj B, Petraki C, **Scorilas A**, Diamandis EP. Valine - Leukine (V89L) mutation of 5a - Thymine - Adenine (TA) repeat polymorphism of the 5a - reductase gene (SRD5A2) and prostate cancer risk. *Proc Eur Soc Urol Res: PSI.7*, 2004.
165. Katsarou M, Thomadaki H, **Scorilas A**, Katsaros N. Expression of SR-A1 gene in response to anticancer therapy. *Anticancer Res, 24: 251*, 2004.
166. Floros K, Thomadaki H, Lallas G, Katsaros N, Talieri M and **Scorilas A**. Cisplatin-Induced Apoptosis in a Promyelocytic (HL-60) Cell Line, Downregulates the Expression of BCL2 and

- Increases the mRNA Levels of the New Member of Apoptosis-Related Genes, BCL2L12. *Proc Apoptosis 2003*: XVI5, 2003.
167. Leoutsakou T, Talieri M, Mathioudaki K, Papadokostopoulou A, Paraskeyas E, Imyanitov E and **Scorilas A**. SR-A1 gene, member of the human pre-mRNA splicing factors, is overexpressed in aggressive colon tumors and may serve as potential indicator of unfavorable prognosis in colon cancer. *Proc Int Prot Soc*: P7-17, 2003.
 168. Mathioudaki K, Talieri M, Papadokostopoulou A, Xynopoulos D, Arnogiannaki N, Agnanti N and **Scorilas A**. Expression of BCL2L12, a new member of apoptosis-related genes, in colon cancer. *Proc Int Prot Soc*: P3-6, 2003.
 169. Floros K, Thomadaki H, Katsaros N, Talieri M and **Scorilas A**. mRNA expression analysis of apoptosis related genes, after treatment of HL-60 cells with carboplatin and doxorubicinin. *Proc Int Prot Soc*: P7-16, 2003.
 170. **Scorilas A**, Chang P, Katsaros D, Yousef G, Diamandis EP. Cloning of a new gene, CEAL1, which encodes for a carcinoembryonic antigen-like protein: overexpression in aggressive ovarian cancer. *Proc Am Assoc Cancer Res*: 1238, 2003.
 171. Nakamura T, **Scorilas A**, Stephan C, Jung K, Soosaipillai A, Diamandis EP. Analysis of serum human kallikrein 11 (hK11) for discriminating between prostate cancer and benign prostatic hyperplasia. *J Urol*: 1439, 2003.
 172. Yousef GM, Polymeris M, Yacoub GM, Fracchioli S, **Scorilas A**, Soosaipillai A, Popalis C, Katsaros D, Diamandis EP. *In silico* analysis of kallikrein gene expression in ovarian cancer. *Clin Chem*: D-23, 2003.
 173. Yousef GM, Borgono C, Polymeris A, Soosaipillai A, **Scorilas A**, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Chan P, Diamandis EP. Human kallikrein 5 (hK5): A novel serum biomarker for ovarian and breast cancer. *Clin Chem*: D-24, 2003.
 174. Yousef G, Borgono C, **Scorilas A**, Fracchioli S, Iskander L, Diamandis EP, Katsaros D. 477 - Prognostic Value of Human Kallikrein Gene 14 (KLK14) in Ovarian Cancer. *Proc Am Assoc Cancer Res*: 477, 2003.
 175. Gregorakis A, Papanastasiou P, Borousas D, Bharai B, Petraki C, **Scorilas A**, Diamandis E. TA Repeat Polymorphism of the 5a Rectudase Gene and Prostate Cancer. *Proc 8th Mediterranean Congress of Urology*, 2003.
 176. Diamandis EP, **Scorilas A**, Yousef G, Kishi T, Luo LY, Nakamura T, Fishman D. Multiparametric serum analysis of human kallikreins hK5, hK6, hK7, hK8, hK10 and hK11 in combination with CA125 for ovarian cancer diagnosis. *Proc Am Assoc Cancer Res*: 478, 2003.
 177. Mathioudaki K, Talieri M, Papadokostopoulou A, Dimitroulopoulos D, Paraskevas E, Xynopoulos D, Arnogiannaki N, Agnanti N, **Scorilas A**. Increased poly(A)polymerase activity levels in colon cancer. *Proc Un Eur Gast Soc*, G-051, 2003.
 178. Papadokostopoulou A, Mathioudaki K, **Scorilas A**, Arnogiannaki N, Tsamakidis K, Kouroumalis E, M Talieri. Expression analysis of protein arginine methyltransferase 1. 11th United European Gastroenterology week. *Proc Un Eur Gast Soc*, G-058, 2003.
 179. Mathioudaki K, Agnanti N, **Scorilas A**, Talieri M. Human protein arginine methyltransferase 1 gene (PRMT1) may serve as a new breast cancer biomarker of unfavorable prognosis. *Proc Int Med Cour Mast*: P- 19, 2003.

180. Mathioudaki K, Ksigi E, Chrisohou M, Ardavanis A, Agnanti N, **Scorilas A**, Talieri M. Expression analysis of a new member of apoptosis-related genes, BCL2L12, in breast cancer. *Proc Int Med Cour Mast P-20*, 2003.
181. Talieri M, Androulakakis A, Mathioudaki K, **Scorilas A**, Karydas I, Arnogiannaki N, Yotis J. Expression analysis of the human protein arginine methyltransferase 1 gene (PRMT1) in breast cancer. *Proc Am Assoc Cancer Res*: 5000, 2003.
182. Kishi T, Grass L, Soosaipillai A, **Scorilas A**, Memari N, Shimizu-Okabe C, Schmitt M, Harbeck N, Dorn J, Schmalfeldt B, Diamandis EP. Human Kallikrein 8 as a Serum Biomarker for Ovarian Cancer. *Proc Am Assoc Cancer Res*: 481, 2003.
183. Nakamura T, **Scorilas A**, Stephan C, Jung K, Soosaipillai A, Miki T, Diamandis EP. The Analysis of Serum Human Kallikrein 11 (hK11) Increases Discrimination between Prostate Cancer and Benign Prostatic Hyperplasia. *Proc Am Assoc Cancer Res*: 2490, 2003.
184. Yousef GM, Borgono C, **Scorilas A**, Ponzzone R, Biglia N, Roagna R, Sismondi P, Diamandis EP. Human Kallikrein Gene 14 (KLK14) Expression: An Indicator of Poor Prognosis in Breast Cancer Patients. *Proc Am Assoc Cancer Res*: 3367, 2003.
185. Nakamura T, Stephan C, **Scorilas A**, Memari N, Yousef GM, Jung K, Diamandis EP. Quantitative Analysis of KLK11 Gene Expression in Prostatic Tissues. *Proc Am Assoc Cancer Res*: 5006, 2003.
186. Nakamura T, **Scorilas A**, Stephan C, Yousef GM, Kristiansen G, Jung K, Diamandis EP. Macrophage Inhibitory Cytokine 1 (MIC-1) Gene is Up-Regulated in Human Prostatic Cancer Tissues. *Proc Am Assoc Cancer Res*: 5019, 2003.
187. Obiezu C, Yousef GM, Jung K, Stephan C, **Scorilas A**, Diamandis EP. Kallikrein gene 5 is differentially expressed in healthy vs. cancerous testicular tissues. *Proc Am Assoc Cancer Res*: 5046, 2003.
188. Borgono C, Yousef GM, **Scorilas A**, Grass L, Soosaipillai A, Diamandis EP. Human Kallikrein 14 (hK14) Expression in Breast Cancer Tissues. *Proc Am Assoc Cancer Res*: 6328, 2003.
189. Yousef GM, Grass L, Polymeris ME, Soosaipillai A, Chan P, **Scorilas A**, Borgono C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Diamandis EP. Human Kallikrein 5 (hK5): A Novel Serum Biomarker for Breast and Ovarian Cancer. *Proc Am Assoc Cancer Res*: 6337, 2003.
190. Yousef GM, Borgoño CA, Robb D, **Scorilas A**, Ponzzone R, Diamandis EP. Human Kallikrein Gene 14 (KLK14) Expression: An Indicator of Poor Prognosis in Breast Cancer Patients. *Proc ACOG, 7th Ann Winter Symp*, 2003.
191. **Scorilas A**, Kletsas D, Diamandis EP. The new member of apoptosis-related proteins, BCL2L12, is down regulated in aggressive breast tumors and in arrested human fibroblasts. *Proc Am Assoc Cancer Res*: 2622, 2002.
192. **Scorilas A**, Diamandis EP, Katsaros N, Gouriotis D, Karida I, Talieri M. Expression analysis of the new member of apoptosis-related proteins, BCL2L12, in breast tumours. *Proc Int Soc Fibr Prot*: 9, 2002.
193. **Scorilas A**, Plebani M, Mazza S, Soosaipillai A, Katsaros N, Basso D, Pagano F, Diamandis EP. Human glandular kallikrein 2 (hk2) and insulin-like growth factor (IGF-1) as discriminating markers between prostate cancer and benign prostatic hyperplasia. *Proc Am Assoc Cancer Res*: 3620, 2002.

194. **Scorilas A**, Diamandis EP, Gouriotis D, Talieri M. Expression analysis of human kallikrein 7 (KLK7) in breast cancer cells. *Proc Int Soc Fibr Prot*: 29, 2002.
195. Kishi T, Grass L, Soosaipillai A, **Scorilas A**, Shimizu-Okde C, Harbeck N, Schmalfeld B, Dorn J, Schmitt M, Diamandis EP. Human Kallikrein 8: Identification and clinical impact in advanced ovarian patients. *Proc Int Soc Fibr Prot*: 405, 2002.
196. Diamandis EP, **Scorilas A**, Yousef GM, Stenman U, Henrik A, Soosaipillai A, Grass L, Katsaros D. Human kallikrein 6: A novel serum biomarker for diagnosis, prognosis and monitoring of ovarian cancer. *Proc Am Assoc Cancer Res*: 3679, 2002.
197. Kyriakopoulou L, **Scorilas A**, Yousef GM, Ponzzone R, Roagna R, Cacciari F, Sismondi P, Diamandis EP. Prognostic significance of human kallikrein 7 (KLK7) in breast cancer. *Proc Am Assoc Cancer Res*: 4548, 2002.
198. Luo LY, Fracchioli S, **Scorilas A**, Grass L, Vergote I, Zee A, Stenman U, Diamandis EP, Katsaros D. Human kallikrein 10 is a new serum marker for ovarian cancer diagnosis and prognosis *Proc Am Assoc Cancer Res*: 3686, 2002.
199. Stephan C, Yousef GM, **Scorilas A**, Jung K, Kristiansen G, Hauptmann S, Garret M. Loening S, Dietel M, Diamandis EP. Hepsin, a potential new marker for prostate cancer. *Proc Am Assoc Cancer Res*: 1935, 2002.
200. Stephan C, Yousef GM, **Scorilas A**, Nakamura T, Kishi T, Jung K, Kristiansen G, Hauptmann S, Diamandis EP. Quantitative analysis of Kallikrein 15 expression in prostate tissue. *Proc Am Assoc Cancer Res*: 5287, 2002.
201. Chang A, Yousef GM, Kapadia C, **Scorilas A**, Ponzzone R, Diamandis EP. Favorable prognostic value of KLK13 gene expression in breast cancer. *Proc Am Assoc Cancer Res*: 230, 2002.
202. Yousef GM, Fracchioli S, Kyriakopoulou L, Zarghooni M, **Scorilas A**, Diamandis M, Puopolo M, Massobrio M, Diamandis EP, Katsaros D, Danese S. A new potential independent prognostic marker for ovarian cancer. *Proc Am Assoc Cancer Res*: 236, 2002.
203. Borgoño CA, Katsaros D, Luo L-Y, Fracchioli S, Yamaguchi N, Soosaipilla A, Grass L, Rigault de la Longrais IA, Puopolo M, Yousef GM, **Scorilas A**, Diamandis EP. The prognostic value of human kallikrein 11 (hK11, trypsin-like serine protease, TLSP) in ovarian cancer cytosols. *Proc Am Assoc Cancer Res*: 237, 2002.
204. Yousef GM, Stephan C, **Scorilas A**, Chang A, Rendl L, Diamandis M, Jung K, Diamandis EP. Down-regulation of the human KLK5 gene in prostate cancer. *Proc Am Assoc Cancer Res*: 3786, 2002.
205. Yousef GM, Memari N, **Scorilas A**, Ponzzone R, Biglia N, Giai M, Roagna R, Sismondi P, Diamandis EP. A new favorable prognostic marker for breast cancer. *Proc Am Assoc Cancer Res*: 4540, 2002.
206. Katsaros D, Fracchioli S, Yousef GM, Luo L-Y, **Scorilas A**, Puopolo M, Stenman U-H, van der Zee AGJ, Vergote I, Diamandis EP. Human kallikrein 6 (hK6) and 10 (hK10): New potential biomarkers for diagnosis and prognosis of epithelial ovarian cancer. *Proc ASCO Meeting 2002*.
207. Luo LY, Katsaros D, **Scorilas A**, Diamandis EP. Serum human kallikrein 10: A novel marker for diagnosis and prognosis of ovarian cancer. *Proc Canadian Lab Med Congress*: P2-05, 2002.
208. Yousef GM, Kyriakopoulou LG, Fracchioli S, Zarghooni M, **Scorilas A**, Diamandis M, Katsaros D, Diamandis EP. A new potential independent prognostic marker for ovarian cancer. *Proc Canadian Lab Med Congress*: P2-06, 2002.

209. Kyriakopoulou LG, **Scorilas A**, Yousef GM, Ponzzone R, Roagna R, Sismondi P, Diamandis EP. Human kallikrein 7 (KLK7) as a prognostic marker in breast cancer. *Proc Canadian Lab Med Congress*: P2-07, 2002.
210. Yousef GM, **Scorilas A**, Borgono C, Fracchioli S, Richiardi G, Massobrio M, Katsaros D, Diamandis EP. Prognostic value of the humankallikrein gene 14 (KLK14) in ovarian cancer. *Clin Chem*: A-78, 2002.
211. Yousef GM, **Scorilas A**, Fracchioli S, Iskander L, Raouf AA, Massobrio M, Katsaros D, Diamandis EP. KLK15 is a new potential independent marker for unfavorable prognosis in ovarian cancer. *Clin Chem* D-118, 2002.
212. Katsaros D, Fracchioli S, Yousef GM, Luo L-Y, **Scorilas A**, Puopolo M, Stenman U-H, van der Zee AGJ, Vergote I, Diamandis EP. Human kallikrein 6 (hK6) and 10 (hK10): New potential biomarkers for diagnosis and prognosis of epithelial ovarian cancer. *Proc ASCO Meeting* 2002.
213. Luo LY, Katsaros D, **Scorilas A**, Diamandis EP. Serum human kallikrein 10: A novel marker for diagnosis and prognosis of ovarian cancer. *Proc Canadian Lab Med Congress*: P2-05, 2002.
214. Yousef GM, Kyriakopoulou LG, Fracchioli S, Zarghooni M, **Scorilas A**, Diamandis M, Katsaros D, Diamandis EP. A new potential independent prognostic marker for ovarian cancer. *Proc Canadian Lab Med Congress*: P2-06, 2002.
215. Kyriakopoulou LG, **Scorilas A**, Yousef GM, Ponzzone R, Roagna R, Sismondi P, Diamandis EP. Human kallikrein 7 (KLK7) as a prognostic marker in breast cancer. *Proc Canadian Lab Med Congress*: P2-07. 2002.
216. Yotis J, **Scorilas A**, Kotsiandri F, Fotiou S, Talieri M. Immunohistochemical staining for Cathepsin B may offer additional prognostic information for ovarian cancer. *Proc Int Prot Soc*: 159, 2001.
217. Yotis J, Pateras Ch, **Scorilas A**, Ardavanis A, Kotsiandri F, Trompetas V, Apostolikas N, Damascou V, Garoyfali A, Agnantis NJ. Hormonal receptor status and HER2/neu expression in bilateral synchronous female breast carcinomas. *Proc Hel Soc Breast Cancer Res*: PB42, 2001.
218. **Scorilas A**, Katsaros D, Kwamie A, Fracchioli S, Diamandis EP. The SR-A1 gene, encoding a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors, is overexpressed in aggressive ovarian tumors and is an independent unfavorable prognostic indicator in ovarian cancer. *Proc Am Assoc Cancer Res*: 3106, 2001.
219. Bharaj B, **Scorilas A**, Giai M, Diamandis EP. Dinucleotide repeat length polymorphism on the 3' untranslated region of the SRD5A2 gene in breast cancer. *Proc Am Assoc Cancer Res*: 2668, 2001.
220. Yousef GM, **Scorilas A**, Jung K, Ashworth L, Diamandis EP. Molecular cloning of a new human kallikrein gene, KLK15, which is up-regulated in prostate cancer. *Proc Am Assoc Cancer Res*: 4017, 2001.
221. Magklara A, **Scorilas A**, Katsaros D, Fracchioli S, Rigault de la Longrais, Piccinno R, Yousef GM, Diamandis EP. The prognostic value of human KLK8 (Neurospisin/Ovasin) in ovarian cancer and evidence for alternative splicing. *Proc Am Assoc Cancer Res*: 4194, 2001.
222. Hoffman B, Katsaros D, **Scorilas A**, Diamandis P, Fracchioli, Rigault de la Longrais I, Diamandis EP. Tumor specific activity of kallikrein 6 protein is a prognostic marker of ovarian carcinoma. *Proc Am Assoc Cancer Res*: 243, 2001.

223. Luo Y, Katsaros D, **Scorilas A**, Fracchioli S, Massobrio M, Diamandis EP. Human kallikrein 10 (hK10, normal epithelial cell-specific 1, NES1) is a new prognostic biomarker for ovarian carcinoma. *Proc Am Assoc Cancer Res*: 3107, 2001.
224. Yousef GM, Kyriakopoulou L, **Scorilas A**, Ponzzone R, Giai M, Sismondi P and Diamandis EP. A novel potential prognostic marker for breast carcinoma. *Proc Am Assoc Clin Chem*: 430, 2001.
225. Kyriakopoulou L, Yousef GM, **Scorilas A**, Katsaros D, Massobrio M, Fracchioli S and Diamandis EP. A novel prognostic marker in ovarian cancer. *Proc Am Assoc Clin Chem*: 437, 2001.
226. Yousef GM, **Scorilas A**, Kyriakopoulou LG, Rendel L, Diamandis M, Ponzzone R, *Diamandis EP*. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. *Proc Can Breast Cancer Res Soc*: 195, 2001.
227. **Scorilas A**, Diamandis EP. Synthesis of a new streptavidin-based macromolecular complex labeled with a europium chelator and its immunoassay applications. *Proc Am Assoc Clin Chem*: 17, 2000.
228. **Scorilas A**, Kyriakopoulou L, and Diamandis EP. Cloning of a human gene, encoding a member of the Ser/Arg-rich family of proteins that interact with RNA Pol-II. *Proc Can Assoc Clin Chem*: 42, 2000.
229. Obiezu CV, **Scorilas A**, Kim H and Diamandis EP. Prostase/KLK-L1 is differentially expressed in normal/benign versus malignant ovarian tissues. *Proc Can Assoc Clin Chem*: 29, 2000
230. **Scorilas A**, Grass L and Diamandis EP. Biotechnology applications using a new streptavidin-based macromolecular complex labeled with a europium chelator (BCPDA) and monoclonal anti-BCPDA antibodies. *Proc Am Assoc Clin Chem*: 82, 2000.
231. **Scorilas A**, Kyriakopoulou L, Yousef GM and Diamandis EP. Mapping, molecular characterization, and tissue expression of a human homolog of the rat A1 gene. *Proc Endocrinol Soc*: 437, 2000.
232. **Scorilas A**, Bharaj B, Hoffman B, Giai M and Diamandis EP. The Genotypes of the 5 α -reductase gene are related with PSA expression and risk in sporadic breast cancer. *Proc Am Assoc Cancer Res*: 5116, 2000.
233. Hoffman B, **Scorilas A**, Diamandis EP, Giai M, Levesque MA and Bharaj B. A prevalent polymorphism in the proximal androgen response element of the prostate specific antigen gene and its implications in breast cancer prognosis. *Proc Am Assoc Cancer Res*: 596, 2000.
234. Magklara A, **Scorilas A**, Catalona WJ and Diamandis EP. Human glandular kallikrein (hK2) and prostate specific antigen (PSA) in prostate and breast cancer. *Proc Am Assoc Cancer Res*: 248, 2000.
235. **Scorilas A**, Bharaj B, Giai M, Diamandis EP. Polymorphisms in the human 5 α -reductase gene and breast cancer. *Proc AACR-NCI-EORTC*: 481, 1999.
236. Magklara A, **Scorilas A**, Catalona WJ and Diamandis EP. The ratio of human glandular kallikrein (hK2) to free PSA as a new potent marker for the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately elevated total PSA levels. *Proc AACR-NCI-EORTC*: 483,1999.
237. **Scorilas A**, Diamandi A, Khosravi MJ, Levesque MA, Lopez-Otin C, De Los Toyos J, Sampedro A, Giai M, Ponzzone R, Roagna R, Sismondi P, Diamandis EP. Determination of pepsinogen C concentration in breast tumor cytosols by a highly sensitive immunofluorometric assay and its association with other prognostic variables. *Clin Chem*: 414, 1999.

238. **Scorilas A**, Karameris A, Arnogiannaki N, Yotis I, Ardavanis A and Talieri M. Overexpression of matrix-metalloproteinase-9 correlates with good prognosis in node-negative breast cancer patients. *Proc Int Proteol Soc*: 42, 1999.
239. **Scorilas A**, Diamandis EP, Levesque MA, Diamandi A, Khosravi MJ, Giai M, Ponzzone R, Roagna R, Sismondi P, Lopez-Otin C. Pepsinogen C, an independent favorable prognostic factor in node-positive breast cancer patients. *Proc Am Assoc Cancer Res*: 1359,1999.
240. Obiezu CV, Giltay EJ, Magklara A, **Scorilas A**, Gooren L, Yu H and Diamandis EP. Dramatic suppression of serum prostate specific antigen and human glandular kallikrein by antiandrogens in male to female transsexuals. *Proc Int Soc Enzym*: 6, 1999.
241. Bharaj B, **Scorilas A**, Hoffman B Giai M, Diamandis EP. A novel ARE-1 polymorphism in the promoter region of the prostate specific antigen gene in both healthy and with breast cancer females. *Clin Chem*, 45: 116,1999.
242. Panagou P, Karameris A, **Scorilas A**, Tsipra S, Kakava D, Tsintiris K, Kalogeropoulos N. Expression of Bcl-X and CD-95 molecules in asthma. *Eur Respir J*: 0811, 1998.
243. Papadopoulou S, Arnogiannaki N, Yiotis I, **Scorilas A**, Balodimou F, Plataniotis G, Agnantis N, Talieri M. Analysis of expression patterns of uPA, PAI-1, Cathepsin B and D in colon cancer. *Proc AACR-APMIS*, B-55,1998.
244. Papadopoulou S, Arnogiannaki N, Besbeas S, Papapanagiotou B, Filopoulos E, Yotis I, Agnantis N, **Scorilas A**, Talieri M. Comparative analysis of expression patterns of uPA, PAI-1, Cathepsin B and matrix metalloproteinase-2 (MMP-2) in colon cancer. *Proc Deuts Forschung*: 20, 1997.
245. Ardavanis A, **Scorilas A**, Pateras C, Garoufali G, Missitzis I, Amanatidou A, Apostolikas N, Rigatos G, Yiotis I. Increased cathepsin-D levels can predict for early treatment failure in breast cancer patients. *Proc Europ Soc Med Oncol*: 59, 1996.
246. **Scorilas A**, Yotis I, Apostolikas N, Gouriotis D, Keramopoulos A, Ampela K, Trangas T and Talieri M. C-erbB-2 amplification and overexpression in breast cancer patients: Correlation to c-myc amplification and overexpression as well as to other prognostic factors. *Proc Mediter Soc Tum Mar Oncol*: 76, 1994.
247. **Scorilas A**, Yotis I, Kourtis N, Ioannidis P, Trangas T and Talieri M. Cathepsin-D levels in breast cancer, relationship with c-myc and c-erbB-2 oncogene amplification and overexpression and node invasiveness. *Anticancer Res*, 12: 433, 1992.

Patents

1. **Scorilas A**, Diamandis EP. Novel BCL2 related proline rich protein (BPR). US Patent. No 09/953352; September 14, 2001.
2. **Scorilas A**, Diamandis EP. Human Ser/Arg-rich protein. US Patent. No 11757.48-US-P1; Jun. 8, 2000.
3. **Scorilas A**, Diamandis EP. Novel testis specific kinase substrate. US Patent. No 11757.47-US-P1; Jun. 8, 2000.
4. **Scorilas A**, Diamandis EP. Novel Adaptin Gene. Pending US Patent No 13780.58 deposited: 7/12/2000.
5. **Scorilas A**, Diamandis EP. Novel carcinoembryonic antigen-like protein, CEAL1 (Submitted to US patent office).

Selected Research Grants

1. Identification and Evaluation of Novel BIOMarkers for Early Diagnosis, PROgnosis, and Treatment MOnitoring of Breast and Prostate Cancers, through the Development of Hypersensitive Molecular Methodologies (BIOPROMO) (*Coordinator*). *Organization*: European Social Fund and Greek Ministry of Education (Thales), 2011-
2. INtegrating the emerging research Potential of the University of Athens Cancer Research Group in the European research area (INsPiRE). (*Partner and WP Coordinator*). *Organization*: Seven Framework Program (FP7), EU (2011-).
3. Expression analysis and study of a novel molecular marker for the laboratory diagnosis, prognosis and treatment response prediction for prostate cancer (*Coordinator*). *Organization*: Ministry of Health and Social Solidarity, 2008-2010.
4. Development of a new prognostic and monitoring method of colon and gastric carcinoma. (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (EPAN, PENED), 2005-2009.
5. Development of a novel molecular methodology for diagnosis, prognosis and treatment response prediction of prostate cancer patients (*Coordinator*). *Organization*: General Secretary for Research and Technology of Greece (EPAN E&T Greece-Canada), 2005-2008.
6. Development and study of novel molecular biomarkers for diagnosis, prognosis and prediction of therapy response in prostate cancer (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (EPAN E&T Greece-Czech Republic), 2005-2007.
7. Development of a novel molecular method for diagnosis, prognosis, and prediction of therapy response in nasopharyngeal cancer (NPC) (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (EPAN E&T Greece-Tunisia), 2005-2007).
8. Health improvement in Serbia through reinforcement of biomedical science and technology. (*Partner*). *Organization*: Six Framework Program (FP6), EU, 2005-2008.
9. Development of a new molecular method for prediction of cytotoxic value of chemotherapeutic drugs through apoptosis induction. (*Coordinator*). *Organization*: European Social Fund and Greek Ministry of Education (EPEAEK II), 2004-2006.
10. Novel Prognostic and Predictive Cancer Markers. (*Partner*). *Organization*: National Institute of Health (NIH), USA, 2004-2006.

11. Development of a new prognostic and monitoring method of breast and ovarian cancer. (*Coordinator*).
Organization: European Social Fund and General Secretary for Research and Technology of Greece (EPAN, PENED), 2002-2006.
12. Expression analysis and study of the role of *BCL2L12*, a newly identified Bcl-2 family member, in sensitivity versus resistance of tumor cells to death-ligand- and drug-induced apoptosis. (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (Greek – Spain Cooperation), 2002-2005.
13. Expression analysis of the novel gene, *SRA1*, in solid tumors: a new cancer biomarker? (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (Greek – Russian Cooperation), 2002-2004.
14. Determination of antimicrobial and cytostatic effect of dinuclear complexes of copper (II) and cobalt (III) with mixed substitutes. (*Coordinator*). *Organization*: European Social Fund and General Secretary for Research and Technology of Greece (Greek - Serbian Cooperation), 2001-2003.